**Consolidated Financial Statements** 

(Unaudited)

**September 30, 2008 and 2007** 

(With Independent Auditors' Review Report)

Consolidated Financial Statements

(Unaudited)

**September 30, 2008 and 2007** 

# **Table of Contents**

	Page
Independent Auditors' Review Report	1
Consolidated Balance Sheets	3
Consolidated Statements of Income	5
Consolidated Statements of Changes in Equity	7
Consolidated Statements of Cash Flows	8
Notes to Consolidated Financial Statements	10

#### **Independent Accountants' Review Report**

Based on a report originally issued in Korean

The Board of Directors and Stockholders KT&G Corporation:

We have reviewed the accompanying consolidated balance sheet of KT&G Corporation and subsidiaries (collectively, the "Company") as of September 30, 2008, and the related consolidated statements of income for the three- and nine-month periods, and the consolidated statements of changes in equity and cash flows for the nine-month periods ended September 30, 2008 and 2007. These consolidated financial statements are the responsibility of the Company's management. Our responsibility is to issue a report on these consolidated financial statements based on our reviews.

We conducted our reviews in accordance with the Review Standards for Semi-annual Financial Statements established by the Securities and Futures Commission of the Republic of Korea. These standards require that we plan and perform the review to obtain moderate assurance as to whether the consolidated financial statements are free of material misstatement. A review consists principally of inquiries of company personnel and analytical procedures applied to financial data and, thus, provides less assurance than an audit. We have not performed an audit and, accordingly, we do not express an audit opinion.

Based on our reviews, nothing has come to our attention that causes us to believe that the consolidated financial statements referred to above are not presented fairly, in all material respects, in accordance with accounting principles generally accepted in the Republic of Korea.

The consolidated balance sheet of the Company as of December 31, 2007 and the related consolidated statements of income, changes in equity and cash flows for the period then ended, which are not accompanying this report, were audited by us and our report thereon, dated February 25, 2008, expressed an unqualified opinion on those statements. The accompanying consolidated balance sheet of the Company as of December 31, 2007, presented for comparative purposes, is not different from that audited by us in all material respects.

The accompanying consolidated financial statements as of and for the nine-month period ended September 30, 2008 have been translated into United States dollars solely for the convenience of the reader. We have reviewed the translation and nothing has come to our attention to suggest that the financial statements expressed in Korean Won have not been translated into dollars on the basis set forth in note 3 to the consolidated financial statements.

The following matters may be helpful to the readers in their understanding of the consolidated financial statements:

As discussed in note 2(a) to the consolidated financial statements, accounting principles and review standards and their application in practice vary among countries. The accompanying consolidated financial statements are not intended to present the financial position, results of operations, changes in equity and cash flows in accordance with accounting principles and practices generally accepted in countries other than the Republic of Korea. In addition, the procedures and practices utilized in the Republic of Korea to review such consolidated financial statements may differ from those generally accepted and applied in other countries. Accordingly, this report and the accompanying consolidated financial statements are for use by those knowledgeable about Korean accounting procedures and review standards and their application in practice.

As discussed in note 24 to the consolidated financial statements, the Company and the Korean government are defendants in lawsuits claiming damages of \(\pm\)759 million for the harmful effects of smoking. The final outcome of these lawsuits cannot be predicted at present. Accordingly, no provisions have been made in the accompanying consolidated financial statements.

As discussed in notes 11 and 24 to the consolidated financial statements, the Company maintains a contract with the farmers under which they are to grow green ginseng and, once the product becomes nine years old, sell the ginseng to the Company. As of September 30, 2008 and December 31, 2007, the balance of advance payments paid to the farmers in accordance with the contract amounted to \(\frac{\pmathbf{H}}{178,998}\) million and \(\frac{\pmathbf{H}}{116,289}\) million, respectively.

As discussed in note 2(a) to the consolidated financial statements, the financial statements of KT&G Tutun Mamulleri Sanayi ve Ticaret A.S. whose total assets as of December 31, 2007 exceeded \(\pmu7,000\) million was included in the Company's consolidated financial statements.

Seoul, Korea November 1, 2008

This report is effective as of November 1, 2008, the review report date. Certain subsequent events or circumstances, which may occur between the review report date and the time of reading this report, could have a material impact on the accompanying consolidated financial statements and notes thereto. Accordingly, the readers of the review report should understand that there is a possibility that the above review report may have to be revised to reflect the impact of such subsequent events or circumstances, if any.

# **Consolidated Balance Sheets**

(Unaudited)

As of September 30, 2008 and December 31, 2007

			2008				2007
In millions of Won and thousands of US dollars	Note		Korean Won		U.S. dollars (note 3)	. <u>-</u>	Korean Won
Assets							
Cash and cash equivalents	23	₩	141,600	\$	119,222	₩	137,687
Short-term financial instruments			1,000		842		1,000
Trade accounts receivable, net of allowance							
for doubtful accounts of <del>W</del> 23,981							
in 2008 and <del>W</del> 11,420 in 2007	5,10,23,24		462,299		389,238		369,804
Other receivables, net of allowance for							
doubtful accounts of ₩5,962 in 2008			47740		40 407		04.055
and <del>W</del> 5,911 in 2007	23		47,742		40,197		34,055
Inventories	6,14		1,224,219		1,030,748		1,317,705
Current portion of long-term loans, net of							
allowance for doubtful accounts of	10		10 467		16,391		10 504
₩0 in 2008 and ₩123 in 2007	10		19,467 8,832		7,436		19,504 17,605
Current deferred tax assets	32		0,032		7,430		17,005
Advance payments, net of allowance for doubtful accounts of <del>W</del> 84 in 2008							
and <del>W</del> 85 in 2007	11,24		85,225		71,757		23,716
Other current assets	7		26,042		21,927		10,920
Total current assets	,	_	2,016,426	_	1,697,758	_	1,931,996
		_	2,010,120	_	1,007,700	_	1,001,000
Available-for-sale securities	8		336,308		283,159		257,098
Equity method investment securities	9		2,486		2,093		35,969
Long-term loans	10		99,148		83,479		99,178
Guarantee deposits paid			56,276		47,382		51,162
Guarantee deposits for membership			23,080		19,432		22,137
Long-term deposits in Escrow Fund	23,24		100,384		84,519		66,633
Property, plant and equipment, net	12,13,14,15		1,617,638		1,361,992		1,559,289
Intangible assets, net	16,17		5,784		4,870		8,659
Long-term advance payments, net of							
allowance for doubtful accounts of							
₩1,411 in 2008 and ₩934 in 2007	11,24		142,465		119,951		96,493
Deferred income tax assets	32		1,433		1,207		1,765
Other non-current assets	18	_	2,921	. <u> </u>	2,459	· -	3,723
Total non-current assets			2,387,923	_	2,010,543		2,202,106
Total assets		₩_	4,404,349	\$_	3,708,301	₩	4,134,102

# KT&G CORPORATION AND SUBSIDIARIES **Consolidated Balance Sheets, Continued** (Unaudited)

As of September 30, 2008 and December 31, 2007

		20	2008			
In millions of Won and thousands of US dollars, except share data	Note	Korean Won	U.S. dollars (note 3)	Korean Won		
Liabilities						
Trade accounts payable	23 ₩	42,402	\$ 35,701	₩ 15,202		
Short-term borrowings	15,20,24	35,200	29,637	38,097		
Advance receipts		8,243	6,940	6,127		
Value added tax payable		146,121	123,028	128,985		
Accrued expenses		38,299	32,246	17,343		
Other payables	23	108,984	91,761	105,693		
Income taxes payable	32	102,642	86,421	220,428		
Tobacco excise and other taxes payable		168,784	142,110	181,734		
Other current liabilities	19	30,698	25,848	17,297		
Total current liabilities		681,373	573,692	730,906		
Long-term borrowings	15,21,24	2,544	2,142	2,733		
Retirement and severance benefits	22	116,711	98,266	86,392		
Guarantee deposits received		22,965	19,336	25,051		
Deferred income tax liabilities	32	154,195	129,827	124,535		
Reserve for sales returns		661	557	894		
Reserve for lawsuit		364	306	364		
Total non-current liabilities		297,440	250,434	239,969		
Total liabilities		978,814	824,126	970,875		
Stockholders' equity						
Common stock of ₩5,000 par value Authorized - 800,000,000 shares Issued - 140,742,497 shares in 2008						
and 143,442,497 shares in 2007						
Outstanding – 129,705,326 shares in 2008		054.050	004 041	054.050		
and 130,839,907 shares in 2007		954,959 471,144	804,041	954,959 465,966		
Capital adjustments	25	•	396,686	465,866		
Capital adjustments	25 26	(306,751)	(258,274)	(414,947)		
Accumulated other comprehensive income	26	52,544	44,240	2,496		
Retained earnings	27	2,233,706	1,880,699	2,134,736		
Minority interest in consolidated subsidiaries		19,933	16,783	20,117		
Total stockholders' equity		3,425,535	2,884,175	3,163,227		
Total liabilities and stockholders' equity	₩	4,404,349	\$ 3,708,301	₩ <u>4,134,102</u>		

# **Consolidated Statements of Income**

(Unaudited)

For the nine-month periods ended September 30, 2008 and 2007

		_	2008			_	2007
In millions of Won and thousands of US dollars, except earnings per share	Note	-	Korean Won	_	U.S. dollars (note 3)	_	Korean Won
Sales	10,28,36	₩	2,453,069	\$	2,065,394	₩	2,267,380
Cost of sales	10,28,30,31	_	1,002,035	_	843,677	_	977,474
Gross profit			1,451,034		1,221,717		1,289,906
Selling, general and administrative expenses	10,29,30,31		593,282		499,522		529,223
Operating income	36	-	857,752	-	722,195	_	760,683
			10.000		15 410		20.000
Interest income			18,306		15,413		30,060
Interest expense			(2,512)		(2,115) (933)		(3,707)
Other bad debt expense Reversal of allowance for doubtful			(1,108)		(933)		(786)
allowance			587		494		404
Gain (loss) on foreign currency			007		10 1		10 1
transactions, net			15,318		12,897		(599)
Gain (loss) on foreign currency			10,010		12,007		(000)
translation, net			46,448		39,108		(1,849)
Gain on sale of property, plant and			•		,		. , ,
equipment, net			11,801		9,936		6,365
Loss on impairment of available-for-							
sale securities	8		-		-		(2,163)
Loss on impairment of property, plant and equipment			(429)		(361)		(2,178)
Provision for Tobacco Production			( /		(00.7		(=, :: =,
Stabilization Fund			_		-		(13,570)
Gain (loss) on prior period							
adjustment	2		2,613		2,200		(20,959)
Gain on valuation of equity method							
investment securities, net	9		187		157		648
Donations	31		(26,468)		(22,285)		(15,523)
Other, net		-	(6,400)	_	(5,388)	_	3,506
Other income		=	58,343	_	49,123	_	(20,351)
Income before income taxes			916,095		771,318		740,332
Income taxes	32	_	267,093	_	224,883	_	228,387
Net income		₩	649,002	\$	546,435	₩	511,945
Controlling Interest in net income Minority interest in losses of	38		649,186		546,590		526,755
consolidated subsidiaries	38		(184)		(155)		(14,810)
Earnings per share							
Basic earnings per share	33	₩ _	4,972	\$ _	4.19	₩_	3,973

# **Consolidated Statements of Income**

(Unaudited)

For the three-month periods ended September 30, 2008 and 2007

		_	2008			_	2007
In millions of Won and thousands of US dollars except earnings per share	Note	_	Korean Won	_	U.S. dollars (note 3)	_	Korean Won
Sales	10,28	₩	852,031	\$	717,379	₩	805,922
Cost of sales	10,28,30,31	_	349,465	_	294,237	_	338,099
Gross profit			502,566		423,142		467,823
Selling, general and administrative expenses	10,29,30,31		215,163		181,159		179,836
Operating income	-, -,,-	-	287,403	_	241,983	=	287,987
Interest income			6,339		5,337		10,240
Interest expense			(687)		(578)		(1,276)
Other bad debt expense			(604)		(509)		(377)
Reversal of allowance for doubtful accounts			-		-		17,898
Loss on impairment of available-for- sale securities	8		-		-		(13)
Gain (loss) on foreign currency transactions, net			8,454		7,118		(407)
Gain (loss) on foreign currency translation, net			30,219		25,443		(1,330)
Gain on sale of property, plant and equipment, net			5,838		4,915		1,385
Loss on impairment of property, plant and equipment			(429)		(361)		(2,178)
Provision for Tobacco Production Stabilization Fund			-		-		(4,634)
Gain on valuation of equity method investment securities, net	9		267		225		399
Gain (loss) on prior period			0.040		0.000		(00.050)
adjustment	2		2,613		2,200		(20,959)
Donations Other, net	31		(8,293) (4,494)		(6,982) (3,784)		(8,577) (1,417)
Other income		_	39,223	_	33,024	_	(11,246)
Income before income taxes			326,626		275,007		276,741
Income taxes	32		96,013		80,839		80,622
Net income		₩	230,614	\$	194,168	₩	196,119
Controlling interest in net income Minority interest in losses of	38		230,523		194,092		198,725
consolidated subsidiaries	38		90		76		(2,606)
Earnings per share							
Basic earnings per share	33	₩_	1,768	\$_	1.49	₩_	1,502

# KT&G CORPORATION AND SUBSIDIARIES Consolidated Statements of Changes in Equity (Unaudited)

For the nine-month periods ended September 30, 2008 and 2007

					Korean Won				
In millions of Won	_	Capital stock	Capital surplus	Capital adjust- ments	Accumu- lated other compre- hensive income	Retained earnings	Minority interest	Total stock holders' equity	
Balance at January 1, 2007	₩	954,959	335,350	(321,904)	15,791	2,061,349	20,218	3,065,763	
Dividends		-	-	(021,004)	10,701	(319,712)	20,210	(319,712)	
Net income		_	_	_	_	526,755	(14,810)	511,945	
Increase in unrealized gain on valuation of available-for-sale securities					7,841	525,755	(11,010)	7,841	
Decrease in unrealized gain on		-	-	-	7,041	-	-	7,041	
valuation of equity method									
investment securities			_	_	(621)			(621)	
Reacquisition of treasury stock				(269,410)	(021)			(269,410)	
Retirement of treasury stock		_	_	269,410	_	(269,410)	_	(200,410)	
Compensation by treasury stock		_	99,465	74,390	_	(200, 110)	_	173,855	
Changes in translation			33, 133	7.7000					
adjustments		-	-	-	802	-	-	802	
Other  Balance at September 30,	-					(97)	(77)	(174)	
2007	₩_	954,959	434,815	(247,514)	23,813	1,998,885	5,331	3,170,289	
					Korean Won				U.S. dollars (note 3)
In millions of Won and thousands of US dollars	<del>-</del>	Capital stock	Capital surplus	Capital adjust- ments	Accumu- lated other compre- hensive income	Retained earnings	Minority interest	Total stock holders' equity	Total stock holders' equity
Balance at January 1, 2008	₩	954,959	465,866	(414,947)	2,496	2,134,736	20,117	3,163,227	2,663,322
Dividends		-	-	· · · · · ·	-	(340,449)	· -	(340,449)	(286,646)
Net income		-	-	-	-	649,186	(184)	649,002	546,437
Increase in unrealized gain on									
valuation of available-for-sale									
securities		-	-	-	43,436	-	-	43,436	36,572
Reacquisition of treasury stock		-	-	(108,889)	-	-	-	(108,889)	(91,681)
Retirement of treasury stock		-	-	209,767	-	(209,767)	-	-	-
Compensation by treasury stock		-	4,375	2,377	-	-	-	6,752	5,685
Changes in translation adjustments Increase in unearned stock		-	-		7,515	-	-	7,515	6,327
compensation		-	-	4,941	-	-	-	4,941	4,159
Other  Balance at September 30,	_	-	903		(903)				
2008	₩	954,959	471,144	(306,751)	52,544	2,233,706	19,933	3,425,535	2,884,175

# **Consolidated Statements of Cash Flows**

(Unaudited)

For the nine-month periods ended September 30, 2008 and 2007

	_	2008			2007
In millions of Won and thousands of US dollars	-	Korean Won	U.S. dollars (note 3)	_	Korean Won
Cash flows from operating activities					
Net income	₩	649,002	\$ 546,435	₩	511,945
Adjustments for:					
Depreciation and amortization		122,248	102,928		114,814
Loss (gain) on valuation of inventories, net		(15,312)	(12,892)		5,175
Bad debt expense		12,977	10,926		4,027
Loss on impairment of available-for-sale securities		-	-		2,163
Gain on valuation of equity method investment securities, net		(187)	(157)		(648)
Loss (gain) on foreign currency translation, net		(46,376)	(39,047)		1,845
Other bad debt expense		1,108	933		786
Reversal of allowance for doubtful accounts		(587)	(494)		(404)
Provision for retirement and severance benefits		47,918	40,346		29,017
Loss (gain) on prior period adjustment		2,613	2,200		20,959
Amortization of present value discounts		-	-		(9,761)
Provision for Tobacco Production Stabilization Fund		-	-		13,570
Other, net		(1,804)	(1,520)		(9,378)
	_	117,372	98,823	_	172,165
	_	_		_	
Change in assets and liabilities:					
Trade accounts receivable		(78,534)	(66,123)		(88,823)
Other receivables		(10,830)	(9,118)		(14,699)
Accrued income		(331)	(279)		(3,404)
Advance payments		(57,708)	(48,588)		(83,924)
Prepaid expenses		(13,733)	(11,563)		(17,405)
Inventories		113,649	95,688		232,721
Long-term advance payments		(48,165)	(40,553)		(36,536)
Trade accounts payable		20,406	17,181		8,587
Other payables		3,234	2,723		12,889
Advance receipts		2,116	1,782		8,190
Withholdings		7,138	6,010		1,902
Value added tax payable		17,135	14,427		19,538
Accrued expenses		26,938	22,681		12,652
Tobacco excise tax and dues payable		(12,950)	(10,903)		550,298
Income taxes payable		(117,854)	(99,229)		35,887
Deferred income taxes, net Deposit for severance benefits trust		20,217 (1,448)	17,022 (1,219)		3,866 2,009
Payments of retirement and severance benefits		(8,801)	(7,410)		(17,800)
Others, net		(1,385)	(1,165)		(17,800)
Net cash provided by operating activities	₩ -		\$ 526,621	₩_	1,309,133
1101 Justi provided by operating activities	<del>∨∨</del> _	020,700	Ψ <u>υζυ,υζι</u>	· · · -	1,000,100

# KT&G CORPORATION AND SUBSIDIARIES Consolidated Statements of Cash Flows, Continued (Unaudited)

For the nine-month periods ended September 30, 2008 and 2007

	_	2008				2007
In millions of Won and thousands of US dollars	-	Korean Won		U.S. dollars (note 3)	_	Korean Won
Cash flows from investing activities						
Proceeds from sale of available-for-sale securities Proceeds from sale of equity method investment	₩	328	\$	276	₩	881
securities		-		-		669
Decrease in short-term financial instruments		-		-		11,940
Decrease (increase) in short-term and long-term loans		86		72		(8,062)
Increase in guarantee deposits, net		(5,124)		(4,314)		(6,731)
Proceeds from sale of property, plant & equipment		18,920		15,930		15,599
Purchases of available-for-sale securities		(20,527)		(17,283)		(219,481)
Increase in long-term deposit in Escrow Fund		(13,394)		(11,277)		(17,500)
Purchases of property, plant & equipment		(147,869)		(124,500)		(181,253)
Purchases of intangible assets		(360)		(303)		(1,289)
Decrease in other investment assets		791		666		1,465
Other, net	-	(871)	_	(733)	_	(406)
Net cash used in investing activities	-	(168,020)	_	(141,467)	_	(404,168)
Cash flows from financing activities						
Decrease in guarantee deposits received, net		(2,054)		(1,729)		(3,360)
Proceeds from short-term borrowings		79,055		66,561		166,610
Proceeds from long-term borrowings		22		19		1,541
Disposal of treasury stock		-		-		201,901
Repayment of short-term borrowings		(84,913)		(71,494)		(172,809)
Repayment of current portion of long-term borrowings		(140)		(118)		-
Reacquisition of treasury stock		(108,889)		(91,681)		(269,410)
Payment of dividends	_	(340,449)	_	(286,646)	_	(319,712)
Net cash used in financing activities	-	(457,368)	_	(385,087)	_	(395,239)
Net increase (decrease) in cash and cash equivalents from change of subsidiaries in consolidated financial		3,836		3,230		(888)
statements		3,030		3,230		(000)
Increase in cash and cash equivalents due to merger	_	-	_		_	415
	-	3,836	_	3,230	_	(473)
Net Increase in cash and cash equivalents		3,913		3,295		509,253
Cash and cash equivalents at beginning of period		137,687		115,927		201,869
Cash and cash equivalents at end of period	₩	141,600	\$	119,222	₩	711,122

# KT&G CORPORATION AND SUBSIDIARIES **Notes to Consolidated Financial Statements** (Unaudited)

September 30, 2008 and 2007

# 1 Organization and Description of Business

KT&G Corporation (the "Parent Company"), which is engaged in manufacturing and selling tobacco, was established on April 1, 1987 as Korea Monopoly Corporation, a wholly-owned enterprise of the Korean government, pursuant to the Korea Monopoly Corporation Act, in order to secure financing and to promote and develop, through efficient management, the monopoly business of red ginseng and tobacco. On April 1, 1989, the Parent Company changed its name to Korea Tobacco and Ginseng Corporation pursuant to the Korea Tobacco and Ginseng Corporation Act. Also, pursuant to the Act on Management Reform and Privatization of Public Enterprises, proclaimed on August 28, 1997 and enforced on October 1, 1997, the Parent Company was excluded from the application of the Act for the Management of Government Invested Enterprises. Accordingly, the Parent Company became an entity existing and operating under the Commercial Code of Korea. The Korean government sold 28,650,000 shares of the Parent Company to the public during 1999 and the Parent Company listed its stock on the Korea Exchange on October 8, 1999. On December 27, 2002, the Parent Company changed its name again from Korea Tobacco & Ginseng Corporation to KT&G Corporation.

As of September 30, 2008, the Parent Company has four manufacturing plants, including the Shin Tan Jin plant, and 14 local headquarters and 168 branches for the sale of tobacco throughout the country. Also, the Parent Company has the Gimcheon plant for fabrication of leaf tobacco and the Chunahn printing plant for the manufacturing of packaging.

Pursuant to the Korean government's privatization program and management reorganization plan, on December 28, 1998, the stockholders approved a plan to separate the Parent Company into two companies by setting up a subsidiary for its red ginseng business segment effective January 1, 1999. The separation was accomplished by the Parent Company's contribution of the assets and liabilities in the red ginseng business segment into a wholly-owned subsidiary, the Korea Ginseng Corporation.

On October 17, 2002 and October 31, 2001, the Parent Company listed 35,816,658 and 45,400,000 Global Depositary Receipts ("GDR") (each GDR representing the right to receive one-half share of common stock of the Parent Company), respectively, on the Luxembourg Stock Exchange pursuant to the Korean government's privatization program.

The ownership of the Parent Company's issued common stock at September 30, 2008 was held as follows:

Stockholder	Number of shares	Percentage of ownership
Industrial Bank of Korea	9,510,485	6.76%
Employee Stock Ownership Association	7,590,405	5.39%
Treasury stock	11,037,171	7.84%
Others	112,604,436	80.01%
	140,742,497	100.00%

The Parent Company has, thus far, reacquired and retired 50,249,400 shares of treasury stock. Accordingly, as of September 30, 2008, the Parent Company's common stock differs from the aggregate par value of issued shares by \text{\text{\$\psi}}251,247 million.

# **Notes to Consolidated Financial Statements** (Unaudited)

September 30, 2008 and 2007

## 2 Summary of Significant Accounting Policies and Basis of Presenting Consolidated Financial Statements

## (a) Basis of Presenting Consolidated Financial Statements

KT&G Corporation and the controlled subsidiaries (hereinafter referred to collectively as the "Company") maintains its accounting records in Korean Won and prepares statutory consolidated financial statements in the Korean language in conformity with accounting principles generally accepted in the Republic of Korea. Certain accounting principles applied by the Company that conform with financial accounting standards and accounting principles in the Republic of Korea may not conform with generally accepted accounting principles in other countries. Accordingly, these financial statements are intended solely for use by only those who are informed about Korean accounting principles and practices. The accompanying consolidated financial statements have been condensed, restructured and translated into English from the Korean language consolidated financial statements.

Certain information included in the Korean language consolidated financial statements, but not required for a fair presentation of the Company's financial position, results of operations or cash flows, is not presented in the accompanying consolidated financial statements.

The Company applied the same accounting policies that were adopted in the previous year's consolidated financial statements.

(i) The consolidated financial statements include the accounts of KT&G and the following controlled subsidiaries as of September 30, 2008 and December 31, 2007. Controlled subsidiaries include entities majority-owned by either KT&G or a controlled subsidiary and other entities where KT&G or its controlled subsidiary owns more than 30% of total outstanding common stock of an investee company and is the largest shareholder. All significant intercompany balances and transactions have been eliminated in consolidation.

Subsidiary	year of establish- ment	Number of shares	Percentage of ownership	Primary business
Korea Ginseng Corporation ("KGC")	1999	12,985,851	100.00%	Manufacturing ginseng products
Korea Ginseng (HK) Limited ("KGHK") (*1) (*2)	1999	18,866,999	99.99%	Sales of ginseng products in Hong Kong
Yungjin Pharm. Ind. Co., Ltd. ("YJPI") (*4)	1962	65,655,051	55.50%	Manufacturing pharmaceutical products
Tae-a Industry Co., Ltd. ("TAI") (*2)	1972	150,000	100.00%	Manufacturing subsidiary material for tobacco
KT&G Tutun Mamulleri Sanayi ve Ticaret A.S. ("KTMST") (*2) (*3)	2003	8,999,888	99.99%	Manufacturing and selling tobacco in Turkey

- (\*1) The ownership percentage in KGHK represents the ownership of this entity by KGC.
- (\*2) The financial statements of KGHK, TAI and KTMST included in consolidation were not reviewed by independent accountants.
- (\*3) KTMST was newly included in the Company's consolidated financial statements since total assets of KTMST as of December 31, 2007 exceeded \(\psi\_7,000\) million.
- (\*4) Yungjin Pharm. Ind. Co., Ltd. restated its financial statements as of and for the year ended December 31, 2006 due to adjustments for the accounting errors made in year 2006 and prior periods resulting in an increase in accumulated deficit by \(\pi\)20,959 million. However, as the effect of the adjustments on the consolidated financial statements was immaterial, the adjusted loss has been charged to current results of operations for the year period ended September 30, 2007.

# **Notes to Consolidated Financial Statements**

(Unaudited)

September 30, 2008 and 2007

# 2 Summary of Significant Accounting Policies and Basis of Presenting Consolidated Financial Statements, Continued

- (a) Basis of Presenting Consolidated Financial Statements, Continued
  - (ii) Significant account balances which occurred in the normal course of business with and between subsidiaries as of September 30, 2008 and December 31, 2007 are summarized as follows (these amounts have been eliminated in consolidation):

In millions of Won

	Transaction Party	Balance Sheet Account		September 30, 2008	December 31, 2007
	ilalisaction Party	Balance Sheet Account	-	30, 2006	31, 2007
KT&G	KTMST	Trade accounts receivable	₩	1,262	-
KT&G	KTMST	Advance payments		19,044	-
KT&G	KGC	Other receivables		1,086	-
KGC	KT&G	Trade accounts receivable		632	270
KGC	KT&G	Guarantee deposits		2,043	2,043
KGC	KT&G	Prepaid expense		58	336
KGC	KGHK	Trade accounts receivable		5,478	5,037
KGC	YJPI	Trade accounts receivable		321	98
YJPI	KGC	Guarantee deposits		212	212
TAI	KT&G	Trade accounts receivable		1,375	-

(iii) Significant transactions which occurred in the normal course of business with and between consolidated subsidiaries for the nine-month periods ended September 30, 2008 and 2007 are summarized as follows (these amounts have been eliminated in consolidation):

In millions of Won

Transaction Party	Income Statement Account	_	2008	2007
KGC	Sales	₩	9,935	1,047
YJPI	Sales		25	65
KTMST	Sales		2,500	-
KGC	Other income		697	10,303
YJPI	Other income		6	1
KT&G	Sales		1,943	1,662
YJPI	Sales		1,362	746
KGHK	Sales		14,936	10,786
TAI	Sales		22	15
KT&G	Sales		5	94
KGC	Sales of property, Plant &		_	9,130
KT&G	Sales		11,387	9,632
	KGC YJPI KTMST KGC YJPI KT&G YJPI KGHK TAI KT&G KGK	KGC Sales YJPI Sales KTMST Sales KGC Other income YJPI Other income KT&G Sales YJPI Sales KGHK Sales KGHK Sales KT&G Sales KGC Sales of property, Plant & equipment	KGC Sales W  YJPI Sales  KTMST Sales  KGC Other income  YJPI Other income  KT&G Sales  YJPI Sales  KGHK Sales  KGHK Sales  KT&G Sales  KGHK Sales  KOHR Sales	KGC         Sales         W         9,935           YJPI         Sales         25           KTMST         Sales         2,500           KGC         Other income         697           YJPI         Other income         6           KT&G         Sales         1,943           YJPI         Sales         1,362           KGHK         Sales         14,936           TAI         Sales         22           KT&G         Sales         5           KGC         Sales of property, Plant & equipment         -

#### **Notes to Consolidated Financial Statements**

(Unaudited)

September 30, 2008 and 2007

# 2 Summary of Significant Accounting Policies and Basis of Presenting Consolidated Financial Statements, Continued

#### (b) Cash Equivalents

The Company considers short-term deposits with maturities of three months or less on acquisition date to be cash equivalents.

# (c) Short-term Deposits

Short-term deposits, (including money market deposit accounts (MMDAs), time deposits, installment savings deposits and restricted bank deposits. etc), are held for short-term cash management purposes, maturing within one year.

#### (d) Allowance for Doubtful Accounts

Allowance for doubtful accounts is estimated based on an analysis of individual accounts and past experience of collection and presented net of trade accounts receivable.

## (e) Inventories

Inventories are stated at the lower of cost or net realizable value. Net realizable value is the estimated selling price in the ordinary course of business, less the estimated selling cost. The cost of inventories is determined by the weighted-average method for finished goods, by-products and work-in-progress; using the moving-average method for raw materials and supplies; and using the specific identification method for goods-in-transit. Also, the cost of construction-in-progress and land involved in pre-contracted sales are determined by the specific identification method. The amount of any write-down of inventories to net realizable value due to obsolescence or excess inventory and other losses of inventories occurring in the normal course of business are recognized as cost of goods sold and such valuation losses are deducted from the inventories as allowance for valuation losses. The Company recognized loss and reversal of loss on valuation of inventories amounting to \text{W4,618} million and \text{W19,930} million, respectively, for the nine-month period ended September 30, 2008. Also, the estimated amounts of inventories in current assets which are not expected to be realized within a period are \text{W155,972} million and \text{W319,217} million, respectively, as of September 30, 2008 and December 31, 2007

The Company recognizes interest costs and other financial charges on borrowings associated with inventories that require a long period in the acquisition, construction or production as an expense in the period in which they are incurred.

# **Notes to Consolidated Financial Statements**

(Unaudited)

September 30, 2008 and 2007

# 2 Summary of Significant Accounting Policies and Basis of Presenting Consolidated Financial Statements, Continued

(f) Investment in Securities (excluding investments in associates, subsidiaries and joint ventures)

#### Classification

Upon acquisition, the Company classifies debt and equity securities (excluding investments in subsidiaries, associates and joint ventures) into the following categories: held-to-maturity, available-for-sale or trading securities.

Investments in debt securities where the Company has the positive intent and ability to hold to maturity are classified as held-to-maturity. Securities that are acquired principally for the purpose of selling in the short term are classified as trading securities. Investments not classified as either held-to-maturity or trading securities are classified as available-for-sale securities.

#### Initial recognition

Investments in securities (excluding investments in subsidiaries, associates and joint ventures) are initially recognized at cost.

#### Subsequent measurement and income recognition

Trading securities are subsequently carried at fair value. Gains and losses arising from changes in the fair value of trading securities are included in the income statement in the period in which they arise. Available-for-sale securities are subsequently carried at fair value. Gains and losses arising from changes in the fair value of available-for-sale securities are recognized as accumulated other comprehensive income, net of tax, directly in equity. Investments in available-for-sale securities that do not have readily determinable fair values are recognized at cost less impairment, if any. Held-to-maturity investments are carried at amortized cost with interest income and expense recognized in the income statement using the effective interest method.

#### Fair value information

The fair value of marketable securities is determined using quoted market prices as of the period end. Fair value of non-marketable debt securities is determined by discounting cash flows using the prevailing market rates for debt with a similar credit risk and remaining maturity. Credit risk is determined using the Company's credit rating as announced by accredited credit rating agencies in Korea. The fair value of investments in money market funds is determined by using quotations obtained by third-party investment management companies.

#### Presentation

Trading securities are presented as current assets. Available-for-sale securities, which mature within one period from the balance sheet date or where the likelihood of disposal within one period from the balance sheet date is probable, are presented as current assets. Held-to-maturity securities, which mature within one period from the balance sheet date, are presented as current assets. All other available-for-sale securities and held-to-maturity securities are presented as long-term investments.

#### **Impairment**

The Company reviews investments in securities whenever events or changes in circumstances indicate that the carrying amount of the investments may not be recoverable. Impairment losses are recognized when the reasonably estimated recoverable amounts are less than the carrying amount and it is not obviously evidenced that impairment is unnecessary.

An impairment loss is reversed if the reversal can be related objectively to an event occurring after the impairment loss was recognized and a reversal of an impairment loss shall not exceed the carrying amount that would have been determined (net of amortization or depreciation) had no impairment loss been recognized in the asset in prior years. For financial assets measured at amortized cost and available-for-sale assets that are debt securities, the reversal is recognized in profit or loss. For available-for-sale financial assets that are equity securities, the reversal is recognized directly in equity.

# **Notes to Consolidated Financial Statements**

(Unaudited)

September 30, 2008 and 2007

# 2 Summary of Significant Accounting Policies and Basis of Presenting Consolidated Financial Statements, Continued

## (g) Investment Securities under the Equity Method of Accounting

Associates are entities of which the Company and its subsidiaries have the ability to significantly influence the financial and operating policies. It is presumed to have significant influence if the Company holds directly or indirectly 20 percent or more of the voting power unless it can be clearly demonstrated that this is not the case. Subsidiaries are entities controlled by the Company.

Investments in associates and subsidiaries are accounted for using the equity method of accounting and are initially recognized at cost.

The Company's investments in associates and subsidiaries include goodwill identified on acquisition (net of any accumulated impairment loss). Goodwill is calculated as the excess of the acquisition cost of an investment in an associate or subsidiary over the Company's share of the fair value of the identifiable net assets acquired. Goodwill is amortized using the straight-line method over its estimated useful life. Amortization of goodwill is recorded together with equity income (losses).

When events or circumstances indicate that the carrying value of goodwill may not be recoverable, the Company reviews goodwill for impairment and records any impairment loss immediately in the statement of income.

The Company's share of its post-acquisition profits or losses in investments in associates and subsidiaries is recognized in the income statement, and its share of post-acquisition movements in equity is recognized in equity. The cumulative post-acquisition movements are adjusted against the carrying amount of each investment. Changes in the carrying amount of an investment resulting from dividends by an associate or subsidiary are recognized when the associate or subsidiary declares the dividend. When the Company's share of losses in an associate or subsidiary equals or exceeds its interest in the associate or subsidiary, including preferred stock or other long term loans and receivables issued by the associate or subsidiary, the Company does not recognize further losses, unless it has incurred obligations or made payments on behalf of the associate or subsidiary.

Except for when the Company discontinues the application of the equity method as the investment in a subsidiary is reduced to zero, net income and net assets of the parent company's separate financial statements should agree with the parent company's share in the net income and net assets of the consolidated financial statements.

Unrealized gains on transactions between the Company and its associate or subsidiaries are eliminated to the extent of the Company's interest in each associate or subsidiary.

# **Notes to Consolidated Financial Statements**

(Unaudited)

September 30, 2008 and 2007

# 2 Summary of Significant Accounting Policies and Basis of Presenting Consolidated Financial Statements, Continued

#### (h) Property, Plant and Equipment

Property, plant and equipment are stated at cost, except in the case of revaluations made in accordance with the Asset Revaluation Law which allowed for asset revaluation prior to the Law being revoked. Assets acquired through an investment-in-kind or a donation, are recorded at their fair value upon acquisition. For assets acquired in exchange for a non-monetary asset, the fair value of the asset given up is used to measure the cost of the asset received unless the fair value of the asset received is more clearly evident.

Significant additions or improvements extending useful lives of assets are capitalized. However, normal maintenance and repairs are charged to expense as incurred.

Depreciation is computed as follows:

	Depreciation method	Useful lives (years)
Buildings	Straight-line method	10 to 60
Structures	Straight-line method	10 to 40
Machinery and equipment Vehicles and other	Straight-line or declining-balance method	2 to 18
transportation equipment	Straight-line or declining-balance method	4 to 5
Tools	Straight-line or declining-balance method	4 to 5
Furniture and fixtures	Straight-line or declining-balance method	4 to 5

The Company recognizes interest cost and other financial charges on borrowings associated with the manufacture, purchase, or construction of property, plant and equipment as an expense in the period in which they are incurred.

The Company reviews the property, plant and equipment for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. An impairment loss would be recognized when the expected estimated undiscounted future net cash flows from the use of the asset and its eventual disposal are less than its carrying amount.

Youngjin Pharm. Ind. Co., Ltd. changed its depreciation method of some buildings, structures and machinery from declining-balance method to straight-line method and recorded the effect of change in the amount of  $\[mu]$ 2,613 as other income since the effect on the consolidated financial statements was judged to be immaterial.

#### (i) Goodwill

Goodwill represents the excess of the cost of an acquisition over the fair value of the identifiable net assets acquired. Goodwill is amortized on a straight-line basis over 5 years. Where it is no longer probable that goodwill will be recovered from the expected future economic benefits generated by the acquisition, it is expensed immediately.

## **Notes to Consolidated Financial Statements**

(Unaudited)

September 30, 2008 and 2007

# 2 Summary of Significant Accounting Policies and Basis of Presenting Consolidated Financial Statements, Continued

#### (j) Intangible Assets, Continued

The criteria for determining whether an incurred cost qualifies as an intangible asset and the periods of amortization for each classification of intangible asset are described below.

## (i) Research and Development Costs

To assess whether an internally generated intangible asset meets the criteria for recognition, the Company classifies the expense generation process into a research phase and a development phase. All costs incurred during the research phase are expensed as incurred. Costs incurred during the development phase are recognized as assets only if the following criteria are met for recognition in Statement of Korea Accounting Standards ("SKAS") No. 3, Intangible Assets: (1) Completion of the intangible asset is technically feasible so that it will be available for use or sale; (2) the Company has the intention and ability to complete the intangible asset and use or sell it; (3) there is evidence that the intangible asset will generate probable future economic benefit; (4) the Company has adequate technical, financial and other resources to complete the development of the intangible asset and the intangible asset will be available; and (5) the expenditures attributable to the intangible asset during its development can be reliably determined. If the costs incurred fail to satisfy these criteria, they are recorded as expenses as incurred.

#### (ii) Other Intangible Assets

Other intangible assets, which consist of industrial property rights, franchise rights and software, are amortized using the straight-line method over 5~15 periods.

## (k) Retirement and Severance Benefits

Employees who have been with the Company for more than one period are entitled to lump-sum payments based on current salary rates and length of service when they leave the Company. The Company's estimated liability under the plan which would be payable if all employees left on the balance sheet date is accrued in the accompanying consolidated balance sheets. A portion of the liability is covered by an employees' severance benefits trust where the employees have a vested interest in the deposit with the insurance company in trust. The deposit for severance benefits held in trust is, therefore, reflected in the accompanying consolidated balance sheets as a reduction of the liability for retirement and severance benefits.

#### (I) Foreign Currency Translation

Monetary assets and liabilities denominated in foreign currencies are translated into Korean Won at the balance sheet date, with the resulting gains or losses recognized in current results of operations. Monetary assets and liabilities denominated in foreign currencies are translated into Korean Won at W1187.7 to US\$1, the rate of exchange on September 30, 2008 that is permitted by the Financial Accounting Standards. Non-monetary assets and liabilities denominated in foreign currencies, which are stated at historical cost, are translated into Korean Won at the foreign exchange rate on the date of the transaction.

Foreign currency assets and liabilities of foreign-based operations and companies accounted for using the equity method are translated at current rate of exchange at the balance sheet date while profit and loss items in the statement of income are translated at average rate and capital account at historical rate. Translation gains and losses arising from collective translation of the foreign currency financial statements of foreign-based operations are recorded net as accumulated other comprehensive income. These gains and losses are subsequently recognized as income in the period the foreign operations or the companies are liquidated or sold.

## **Notes to Consolidated Financial Statements**

(Unaudited)

September 30, 2008 and 2007

# 2 Summary of Significant Accounting Policies and Basis of Presenting Consolidated Financial Statements, Continued

#### (m) Valuation of Receivables and Payables at Present Value

Receivables and payables arising from long-term cash loans/borrowings and other similar transactions are stated at present value. The difference between the nominal value and present value of related receivables or payables is amortized using the effective interest method. The amount amortized is included in interest expense or interest income.

# (n) Revenue Recognition

The Company's revenue categories consist of tobacco products sold, construction contracts and other income.

#### Tobacco products sold

Revenue from the sale of tobacco products is measured at the fair value of the consideration received or receivable, net of returns and allowances, trade discounts and volume rebates. Revenue is recognized when the significant risks and rewards of ownership have been transferred to the buyer, recovery of the consideration is probable, the associated costs and possible return of goods can be estimated reliably, and there is no continuing management involvement with the goods.

#### Lotting-out construction contracts

When the outcome of a lotting-out construction contract can be estimated reliably, contract revenue and expenses are recognized in the statement of income in proportion to the percentage of completion and sales of lots of the contact. Lotting-out revenue includes the initial amount agreed in the contract plus any variations in contract work, claims and incentive payments to the extent that it is probable that they will result in revenue and can be measured reliably.

The percentage of completion is assessed by reference to costs incurred for work performed to date to the estimated total contract costs. When the outcome of a construction contract cannot be estimated reliably, revenue is recognized only to the extent of contract costs incurred that are likely to be recoverable. An expected loss on a contract is recognized immediately in the statement of income.

Revenue from other than the above is recognized when the Company's revenue-earning activities are substantially completed, the amount of revenue can be measured reliably, and it is probable that the economic benefits associated with the transaction will flow to the Company.

#### (o) Income Taxes

Income taxes on the income or loss for the periods comprises current and deferred tax. Income taxes are recognized in the consolidated statements of income except to the extent that it relates to items recognized directly in equity, in which case it is recognized in equity.

Current income tax is the expected tax payable on the taxable income for the period, using tax rates enacted.

Deferred tax is provided using the asset and liability method, providing for temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for tax purposes. The amount of deferred tax provided is based on the expected manner of realization or settlement of the carrying amount of assets and liabilities, using tax rates enacted or substantially enacted at the balance sheet date.

A deferred tax asset is recognized only to the extent that it is probable that future taxable income will be available against which the unused tax losses and credits can be utilized. Deferred tax assets are reduced to the extent that it is no longer probable that the related tax benefit will be realized.

## **Notes to Consolidated Financial Statements**

(Unaudited)

September 30, 2008 and 2007

# 2 Summary of Significant Accounting Policies and Basis of Presenting Consolidated Financial Statements, Continued

#### (o) Income Taxes, Continued

Deferred tax assets and liabilities are classified as current or non-current based on the classification of the related asset or liability for financial reporting or the expected reversal date of the temporary difference for those with no related asset or liability such as loss carryforwards and tax credit carryforwards. The deferred tax amounts are presented as a net current asset or liability and a net non-current asset or liability.

Deferred taxes are recognized on the temporary differences related to unrealized gains and losses on investment securities that are reported as a separate component of capital adjustments.

#### (p) Provisions, Contingent Assets and Contingent Liabilities

Provisions are recognized when all of the following are met: (1) an entity has a present obligation as a result of a past event, (2) it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation, and (3) a reliable estimate can be made of the amount of the obligation. Where the effect of the time value of money is material, a provision is recorded at the present value of the expenditures expected to be required to settle the obligation.

Where the expenditure required to settle a provision is expected to be reimbursed by another party, the reimbursement is recognized as a separate asset when, and only when, it is virtually certain that reimbursement will be received if the Company settles the obligation. The expense relating to a provision is presented net of the amount recognized for a reimbursement.

## (q) Prior Period Adjustments

Prior period adjustments resulting from other than fundamental errors are charged or credited to net income for the current period. The fundamental errors are defined as errors with such a significant effect on the financial statements for one or more prior periods that those financial statements can no longer be considered to have been reliable at the date of their issue. The prior period adjustments resulting from the fundamental errors are charged or credited to the beginning balance of retained earnings, and the financial statements of the prior year are restated.

# (r) Earnings Per Share

Earnings per common share are calculated by dividing net income by the weighted-average number of shares of common stock outstanding during each period.

#### (s) Share-based Payments

The Company has granted shares or share options to its employees and other parties. For equity-settled share-based payment transactions, the Company measures the goods or services received, and the corresponding increase in equity as a capital adjustment at the fair value of the goods or services received, unless that fair value cannot be estimated reliably. If the entity cannot estimate reliably the fair value of the goods or services received, the Company measures their value, and the corresponding increase in equity, indirectly, by reference to the fair value of the equity instruments granted. If the fair value of the equity instruments cannot be estimated reliably at the measurement date, the Company measures them at their intrinsic value and recognizes the goods or services received based on the number of equity instruments that ultimately vest. For cash-settled share-based payment transactions, the Company measures the goods or services acquired and the liability incurred at the fair value of the liability. Until the liability is settled, the Company remeasures the fair value of the liability at each reporting date and at the date of settlement, with changes in fair value recognized in profit or loss for the period.

#### **Notes to Consolidated Financial Statements**

(Unaudited)

September 30, 2008 and 2007

## 2 Summary of Significant Accounting Policies and Basis of Presenting Consolidated Financial Statements, Continued

#### (t) Derivatives

The Company holds derivative financial instruments to hedge its foreign currency and interest rate risk exposures. Embedded derivatives are separated from the host contract and accounted for separately if the economic characteristics and risks of the host contract and the embedded derivative are not closely related, and a separate instrument with the same terms as the embedded derivative would meet the definition of a derivative.

Derivatives are initially recognized at fair value on the date on which a derivative contract is entered into and are subsequently remeasured at their fair value. Attributable transaction costs are recognized in profit or loss when incurred.

#### Hedge accounting

Where a derivative, which meets certain criteria, is used for hedging the exposure to changes in the fair value of a recognized asset, liability or firm commitment, it is designated as a fair value hedge. Where a derivative, which meets certain criteria, is used for hedging the exposure to the variability of the future cash flows of a forecasted transaction it is designated as a cash flow hedge.

The Company documents, at the inception of the transaction, the relationship between hedging instruments and hedged items, as well as its risk management objective and strategy for undertaking various hedge transactions. The Company also documents its assessment, both at hedge inception and on an ongoing basis, of whether the derivatives that are used in hedging transactions are highly effective in offsetting the changes in fair values or cash flows of hedged items.

## Fair value hedge

Changes in the fair value of derivatives that are designated and qualify as fair value hedges are recorded in the statement of income, together with any changes in the fair value of the hedged asset or liability that are attributable to the hedged risk.

#### Cash flow hedge

The effective portion of changes in the fair value of derivatives that are designated and qualify as cash flow hedges is recognized in equity. The gain or loss relating to any ineffective portion is recognized immediately in the statement of income. Amounts accumulated in equity are recycled to the income statement in the periods in which the hedged item will affect profit or loss. When a hedging instrument expires or is sold, or when a hedge no longer meets the criteria for hedge accounting, any cumulative gain or loss existing in equity at the time remains in equity and is recognized when the forecast transaction is ultimately recognized in the statement of income. When a forecast transaction is no longer expected to occur, the cumulative gain or loss that was reported in equity is immediately transferred to the statement of income.

## Derivatives that do not qualify for hedge accounting

Changes in the fair value of derivative instruments that are not designated as fair value or cash flow hedges are recognized immediately in the statement of income.

# Separable embedded derivatives

Changes in the fair value of separable embedded derivatives are recognized immediately in the statement of income.

## **Notes to Consolidated Financial Statements**

(Unaudited)

September 30, 2008 and 2007

# 2 Summary of Significant Accounting Policies and Basis of Presenting Consolidated Financial Statements, Continued

#### (u) Use of Estimates

The preparation of consolidated financial statements in accordance with accounting principles generally accepted in the Republic of Korea requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and related notes to consolidated financial statements. Actual results could differ from those estimates.

# (v) Minority Interest in Consolidated Subsidiaries

Minority interest in consolidated subsidiaries is presented as a separate component of stockholders' equity in the consolidated balance sheets.

#### 3 Basis of Translating Consolidated Financial Statements

The consolidated financial statements are expressed in Korean Won and, solely for the convenience of the reader, have been translated into United States dollars at the rate of W1187.7 to US\$1, the basic exchange rate on September 30, 2008. This translation should not be construed as a representation that any or all of the amounts shown could be converted into U.S. dollars at this or any other rate.

#### 4 Restricted Deposits

Financial instruments restricted in use as security for maintaining checking accounts as of September 30, 2008 and December 31, 2007 are summarized as follows:

In millions of Won	September 30, 2008		December 31, 2007	
Long-term financial instruments	₩	8	8	

# 5 Transfers of Trade Accounts Receivable

Certain of export trade accounts and notes receivable transferred to and discounted with third parties as of September 30, 2008 and December 31, 2007 are summarized as follows:

In millions of Won	Ser ——	September 30, 2008	
Export trade accounts receivable Notes receivable	₩	137 6,560	2,795 <u>7,056</u>
	₩	6,697	9,851

# **Notes to Consolidated Financial Statements**

(Unaudited)

September 30, 2008 and 2007

# 6 <u>Inventories</u>

Inventories as of September 30, 2008 and December 31, 2007 are summarized as follows:

In millions of Won	S	eptember 30, 2008	December 31, 2007
Merchandise, net of allowance for valuation losses Finished goods, net of allowance for valuation losses Semi-finished goods Work-in-progress, net of allowance for valuation losses Raw materials, net of allowance for valuation losses Subsidiary material, net of allowance for valuation losses Supplies By-products Unsold buildings (note 28)	₩	939 159,438 11,671 188,591 720,955 905 21,834 2,867 85,941	1,107 134,164 20,170 259,059 804,741 548 21,856 2,641 52,150
Sites for building lotting-out construction (notes 13 and 28 Goods-in-transit	3)	14,519 16,558	13,204 8,065
	₩	1,224,219	1,317,705

# 7 Other Current Assets

Other current assets as of September 30, 2008 and December 31, 2007 are summarized as follows:

In millions of Won	_	September 30, 2008	December 31, 2007
Accrued income	₩	658	326
Prepaid expenses		23,135	9,374
Prepaid income taxes		103	34
Short-term loans, net of allowance for			
doubtful accounts of $\ensuremath{W}$ 125 in 2008 and $\ensuremath{W}$ 0 in 2007		1,073	1,094
Available-for-sale securities (note 8)	_	1,073	92
	₩	26,042	10,920

# **Notes to Consolidated Financial Statements**

(Unaudited)

September 30, 2008 and 2007

# 8 Available-for-sale Securities

Available-for-sale securities as of September 30, 2008 and December 31, 2007 are summarized as follows:

# (a) Equity securities (non-current)

Mumbor of shares         Numbor of shares         of shares         Acquisition cost         Fair value         September 31, 2007           Marketable securities:         Vinnap Television News (YTN)         8,380,000         119.95% ₩ 5,102         39,805         39,805         28,366           Crystal Genomics Co., Ltd.         172,187         1.67%         3.022         1,715         1,715         1,791           Oscotech, Inc.         230,770         3.51%         2.250         1,027         1,027         1,396           Shinhan Financial Group         3,500,000         0.88%         205,532         146,650         146,650         187,250           EKZHHN Pharmaceuticals, Inc.(*1)         14,642,858         8.28%         5,158         7,114         7,114         -           Celltrion, Inc. (*1)         13,030,810         12,23%         21,245         108,807         108,807         -           Celltrion, Inc. (*1)         13,030,810         112,23%         21,245         108,807         108,807         -         -         -         -         -         -         21,245         18,000         118,000         40,00%         2,540         -         -         -         -         -         -         -         -         -		Percentage				Book value	
Vonhap Television News (YTN)         8,380,000         19,95% ₩         5,102         39,805         39,805         28,366           Crystal Genomics Co., Ltd.         172,187         1,67%         3,022         1,715         1,715         1,791           Oscotech, Inc.         230,770         3,51%         2,250         1,027         1,396           Shinhan Financial Group         3,500,000         0.88%         205,532         146,650         146,650         187250           REXAHN Pharmaceuticals, Inc. (*1)         4,642,858         8.28%         5,158         7114         7114         -           Celltrion, Inc. (*1)         13,030,810         12.23%         21,245         108,807         108,807         -           Celltrion, Inc. (*1)         13,030,810         12.23%         21,245         108,807         108,807         -         -           Non-marketable securities:         2         2,42,309         305,118         305,118         218,803           Non-marketable securities:         2         2         2,242,309         305,118         305,118         218,803           Non-marketable securities:         2         2         2,260         2,560         -         -         -         -         2,12,45 </th <th></th> <th></th> <th>of</th> <th>_</th> <th></th> <th></th> <th></th>			of	_			
Vonhap Television News (YTN)         8,380,000         19,95% ₩         5,102         39,805         39,805         28,366           Crystal Genomics Co., Ltd.         172,187         1,67%         3,022         1,715         1,715         1,791           Oscotech, Inc.         230,770         3,51%         2,250         1,027         1,396           Shinhan Financial Group         3,500,000         0.88%         205,532         146,650         146,650         187250           REXAHN Pharmaceuticals, Inc. (*1)         4,642,858         8.28%         5,158         7114         7114         -           Celltrion, Inc. (*1)         13,030,810         12.23%         21,245         108,807         108,807         -           Celltrion, Inc. (*1)         13,030,810         12.23%         21,245         108,807         108,807         -         -           Non-marketable securities:         2         2,42,309         305,118         305,118         218,803           Non-marketable securities:         2         2         2,242,309         305,118         305,118         218,803           Non-marketable securities:         2         2         2,260         2,560         -         -         -         -         2,12,45 </td <td>Marketable securities:</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>	Marketable securities:						
Crystal Genomics Co., Ltd.         172,187         1.67%         3,022         1,715         1,715         1,791           Oscotech, Inc.         230,770         3,51%         2,250         1,027         1,027         1,396           Shinhan Financial Group         3,500,000         0.88%         205,532         146,650         146,650         187,250           REXAHN Pharmaceuticals, Inc.(*1)         4,642,858         8.28%         5,158         7,114         7,114         -           Celltrion, Inc. (*1)         13,030,810         12,23%         21,245         108,807         108,807         -           Non-marketable securities:		8.380.000	19.95% ₩	<del>√</del> 5.102	39.805	39.805	28.366
Oscotech, Inc.         230,770         3.51%         2,250         1,027         1,027         1,396           Shinhan Financial Group         3,500,000         0.88%         205,532         146,650         187,250           REXAHN Pharmaceuticals, Inc. (*1)         13,030,810         12.23%         51,58         7,114         7,114         -           Celltrion, Inc. (*1)         13,030,810         12.23%         21,245         108,807         108,807         -           Non-marketable securities:         Celltrion, Inc. (*1)         - 22,2309         305,118         305,118         218,803           Non-marketable securities:         Celltrion, Inc. (*1)         - 2         - 21,245         - 2 <td></td> <td></td> <td></td> <td>•</td> <td>· ·</td> <td></td> <td></td>				•	· ·		
Shinhan Financial Group         3,500,000         0.88%         205,532         146,650         146,650         187250           REXAHN Pharmaceuticals, Inc. (*1)         4,642,858         8.28%         5,158         7,114         7,114         -           Celltrion, Inc. (*1)         13,030,810         12.23%         21,245         108,807         108,807         -           Non-marketable securities:         Celltrion, Inc. (*1)         - 242,309         305,118         305,118         218,803           Non-marketable securities:         Celltrion, Inc. (*1)         - 242,309         305,118         305,118         218,803           Nexgen Biotechnologies, Inc. (*3)         1,000,000         11.84%         2,150         -							
REXAHN Pharmaceuticals, Inc. (*1)							
Celltrion, Inc. (*1)	·			•			-
Non-marketable securities:   Celltrion, Inc. (*1)   -							_
Non-marketable securities:   Celltrion, Inc. (*1)   -   -   -   -   -   -   -   -   -	Controll, me. ( 1)	10,000,010	.2.20 / 0				210 002
Celltrion, Inc. (*1)         -         -         -         -         -         2         21,245           Nexgen Biotechnologies, Inc. (*3)         1,000,000         11.84%         2,150         -         -         -           Cosmo Tobacco Co., Ltd. (*3)         480,000         40.00%         2,540         -         -         -           Innodis, Inc.         110,000         19.64%         55         55         55         55           REXAHN Pharmaceuticals, Inc. (*1)         -         -         -         -         -         5,158           Lifenza, Inc. (*3)         29,047         13.01%         1,600         -         -         -         5,158           Korea Islet Transplantation         Institute, Inc. (*2)         110,500         48.25%         2,000         2,000         2,000         2,000           Korea Tabacos do Brasil Ltda. (*2)         (*6)         99.90%         394         394         394         394         394           Genematrix, Inc.         300,000         10.14%         1,500         1,500         1,500         1,500           Litepharmtech, Inc. (*2)         77,667         29.46%         1,830         1,830         1,830           Hurum, Inc.	Non-marketable securities:			242,309	300,110	300,116	210,003
Nexgen Biotechnologies, Inc. (*3)         1,000,000         11.84%         2,150         -         -         -           Cosmo Tobacco Co., Ltd.(*3)         480,000         40.00%         2,540         -         -         -           Innodis, Inc.         110,000         19.64%         55         55         55         55           REXAHN Pharmaceuticals, Inc.(*1)         -         -         -         -         -         5,158           Lifenza, Inc. (*3)         29,047         13.01%         1,600         -         -         -         5,158           Korea Islet Transplantation         110,500         48.25%         2,000         1,000         2,000         2,000         2,000         1,000         <		_	_	_	_	_	21 245
Cosmo Tobacco Co., Ltd.(*3)         480,000         40.00%         2,540         -         5,158           EKAHN Pharmaceuticals, Inc. (*3)         29,047         13.01%         1,600         -		1 000 000	11.84%	2 150	_	_	21,210
Innodis, Inc.   Innodis,					_	_	_
REXAHN Pharmaceuticals, Inc. (*1)         1         -         -         -         -         -         5,158           Lifenza, Inc. (*3)         29,047         13.01%         1,600         -         -         -         -           Korea Islet Transplantation         110,500         48.25%         2,000         3,04         394         394         394         394         394         394         394         394         394         394         394         394         394         394         394         394         394					55	55	55
Lifenza, Inc. (*3)         29,047         13.01%         1,600         -         -         -           Korea Islet Transplantation Institute, Inc. (*2)         110,500         48.25%         2,000         2,000         2,000         2,000           KT&G Mongolia LLC (*4)         -         -         -         -         -         -         201           Korea Tabacos do Brasil Ltda. (*2)         (*6)         99.90%         394         394         394         394           Genematrix, Inc.         300,000         10.14%         1,500         1,500         1,500         1,500           Litepharmtech, Inc. (*2)         77,667         29.46%         1,830         1,830         1,830         1,830           Hurum, Inc.         7,800         9.75%         39         39         39         39         39           Mazence Co., Ltd.         197,556         6.86%         733         7		110,000	10.0170	-	-	-	
Korea Islet Transplantation Institute, Inc. (*2)         110,500         48.25%         2,000         2,000         2,000         2,000           KT&G Mongolia LLC (*4)         -         -         -         -         -         -         201           Korea Tabacos do Brasil Ltda. (*2)         (*6)         99.90%         394         394         394         394           Genematrix, Inc.         300,000         10.14%         1,500         1,500         1,500         1,500           Litepharmtech, Inc. (*2)         77,667         29.46%         1,830         1,830         1,830         1,830           Hurum, Inc.         7,800         9.75%         39		29 047	13 01%	1 600		_	5,150
Institute, Inc. (*2)         110,500         48.25%         2,000         2,000         2,000         2,000           KT&G Mongolia LLC (*4)         -         -         -         -         -         -         201           Korea Tabacos do Brasil Ltda. (*2)         (*6)         99.90%         394         394         394         394           Genematrix, Inc.         300,000         10.14%         1,500         1,500         1,500         1,500           Litepharmtech, Inc. (*2)         77,667         29.46%         1,830         1,830         1,830         1,830           Hurum, Inc.         7,800         9.75%         39         39         39         39           Mazence Co., Ltd.         197,556         6.86%         733         733         733         733           OCT USA, Inc.         48,780         19.97%         927         927         927         927           Dream Hub PFV Co., Ltd.         3,000,000         1.50%         15,000         15,000         75           Migami, Inc.         4,286,000         3.77%         2,830         2,830         2,830         2           KT&G Pars (*2)         (*6)         99.09%         479         479         479		23,047	10.01 70	1,000		_	_
KT&G Mongolia LLC (*4)         -         -         -         -         -         201           Korea Tabacos do Brasil Ltda. (*2)         (*6)         99.90%         394         394         394         394           Genematrix, Inc.         300,000         10.14%         1,500         1,500         1,500         1,500           Litepharmtech, Inc. (*2)         77,667         29.46%         1,830         1,830         1,830         1,830           Hurum, Inc.         7,800         9.75%         39         39         39         39           Mazence Co., Ltd.         197,556         6.86%         733         733         733         733           OCT USA, Inc.         48,780         19.97%         927         927         927         927           Dream Hub PFV Co., Ltd.         3,000,000         1.50%         15,000         15,000         75           Migami, Inc.         4,286,000         3.77%         2,830         2,830         2,830           KT&G Pars (*2)         459,998         99.99%         479         479         479           KT&G Rus L.L.C. (*2)         (*6)         99.00%         793         793         793         -           SJ Biomed Corpor	·	110.500	48.25%	2.000	2.000	2.000	2.000
Korea Tabacos do Brasil Ltda. (*2)         (*6)         99.90%         394         394         394         394           Genematrix, Inc.         300,000         10.14%         1,500         1,500         1,500           Litepharmtech, Inc. (*2)         77,667         29.46%         1,830         1,830         1,830           Hurum, Inc.         7,800         9.75%         39         39         39         39           Mazence Co., Ltd.         7,800         9.75%         39         39         39         39           Mazence Co., Ltd.         7,800         9.75%         39         39         39         39           Mazence Co., Ltd.         19.7556         6.86%         733         733         733         733           OCT USA, Inc.         48,780         19.97%         927         927         927         927           Dream Hub PFV Co., Ltd.         3,000,000         1.50%         15,000         15,000         15,000         75           Migami, Inc.         4,286,000         3.77%         2,830         2,830         2,830         -           KT&G Pars (*2)         459,998         99.99%         479         479         479         -		-	-	-	-	-	
Genematrix, Inc.         300,000         10.14%         1,500         1,500         1,500         1,500           Litepharmtech, Inc. (*2)         77,667         29.46%         1,830         1,830         1,830         1,830           Hurum, Inc.         7,800         9.75%         39         39         39         39           Mazence Co., Ltd.         7,800         9.75%         39         39         39         39           Mazence Co., Ltd.         19,7556         6.86%         733         733         733         733           OCT USA, Inc.         48,780         19.97%         927         927         927         927           Dream Hub PFV Co., Ltd.         3,000,000         1.50%         15,000         15,000         15,000         75           Migami, Inc.         4,286,000         3,77%         2,830         2,830         2,830         -           KT&G Pars (*2)         459,998         99.99%         479         479         479         479         -           KT&G Rus L.L.C. (*2)         (*6)         99.00%         793         793         793         -           Korea Carbon Finance, Inc.(*2)         100,000         20.00%         500         500	Korea Tabacos do Brasil Ltda. (*2)	(*6)	99.90%	394	394	394	
Litepharmtech, Inc. (*2)         77,667         29.46%         1,830         1,830         1,830         1,830           Hurum, Inc.         7,800         9.75%         39         39         39         39           Mazence Co., Ltd.         (formerly, MD Bioalpha Co., Ltd.)         197,556         6.86%         733         733         733         733           OCT USA, Inc.         48,780         19.97%         927         927         927         927           Dream Hub PFV Co., Ltd.         3,000,000         1.50%         15,000         15,000         15,000         75           Migami, Inc.         4,286,000         3.77%         2,830         2,830         2,830         -           KT&G Pars (*2)         459,998         99.99%         479         479         479         -           KT&G Rus L.L.C. (*2)         (*6)         99.00%         793         793         793         -           Korea Carbon Finance, Inc.(*2)         100,000         20.00%         500         500         500         -           SJ Biomed Corporation         285,714         16.00%         1,000         1,000         1,000         -           The Korea Economic Daily         287         0.00%			10.14%				
Hurum, Inc.         7,800         9.75%         39         39         39         39           Mazence Co., Ltd.         (formerly, MD Bioalpha Co., Ltd.)         197,556         6.86%         733         733         733         733           OCT USA, Inc.         48,780         19.97%         927         927         927         927           Dream Hub PFV Co., Ltd.         3,000,000         1.50%         15,000         15,000         15,000         75           Migami, Inc.         4,286,000         3.77%         2,830         2,830         2,830         -           KT&G Pars (*2)         459,998         99.99%         479         479         479         -           KT&G Rus L.L.C. (*2)         (*6)         99.00%         793         793         793         -           Korea Carbon Finance, Inc.(*2)         100,000         20.00%         500         500         500         -           SJ Biomed Corporation         285,714         16.00%         1,000         1,000         1,000         -           The Korea Economic Daily         287         0.00%         5         5         5         5           Ddrug Co., Ltd. (*5)         -         -         -         - <td>Litepharmtech, Inc. (*2)</td> <td></td> <td>29.46%</td> <td></td> <td></td> <td></td> <td></td>	Litepharmtech, Inc. (*2)		29.46%				
Mazence Co., Ltd.       (formerly, MD Bioalpha Co., Ltd.)       197,556       6.86%       733       733       733       733         OCT USA, Inc.       48,780       19.97%       927       927       927       927         Dream Hub PFV Co., Ltd.       3,000,000       1.50%       15,000       15,000       15,000       75         Migami, Inc.       4,286,000       3.77%       2,830       2,830       2,830       -         KT&G Pars (*2)       459,998       99.99%       479       479       479       -         KT&G Rus L.L.C. (*2)       (*6)       99.00%       793       793       793       -         Korea Carbon Finance, Inc.(*2)       100,000       20.00%       500       500       500       -         SJ Biomed Corporation       285,714       16.00%       1,000       1,000       1,000       -         The Korea Economic Daily       287       0.00%       5       5       5       5         Ddrug Co., Ltd. (*5)       -       -       -       -       -       -       -         Yungjin Co., Ltd. (*3)       16,760       41.90%       168       -       -       -       -	Hurum, Inc.	· ·					
OCT USA, Inc.         48,780         19.97%         927         927         927         927           Dream Hub PFV Co., Ltd.         3,000,000         1.50%         15,000         15,000         15,000         75           Migami, Inc.         4,286,000         3.77%         2,830         2,830         2,830         -           KT&G Pars (*2)         459,998         99.99%         479         479         479         -           KT&G Rus L.L.C. (*2)         (*6)         99.00%         793         793         793         -           Korea Carbon Finance, Inc.(*2)         100,000         20.00%         500         500         500         -           SJ Biomed Corporation         285,714         16.00%         1,000         1,000         1,000         -           The Korea Economic Daily         287         0.00%         5         5         5         5           Ddrug Co., Ltd. (*5)         -         -         -         -         -         -         -         -           Yungjin Co., Ltd. (*3)         16,760         41.90%         168         -         -         -         -	Mazence Co., Ltd.	,					
Dream Hub PFV Co., Ltd.         3,000,000         1.50%         15,000         15,000         15,000         75           Migami, Inc.         4,286,000         3.77%         2,830         2,830         2,830         -           KT&G Pars (*2)         459,998         99.99%         479         479         479         -           KT&G Rus L.L.C. (*2)         (*6)         99.00%         793         793         793         -           Korea Carbon Finance, Inc.(*2)         100,000         20.00%         500         500         500         -           SJ Biomed Corporation         285,714         16.00%         1,000         1,000         1,000         -           The Korea Economic Daily         287         0.00%         5         5         5         5           Ddrug Co., Ltd. (*5)         -         -         -         -         -         -         -         -         4           Husis Co., Ltd. (*3)         16,760         41.90%         168         -         -         -         -	(formerly, MD Bioalpha Co., Ltd.)	197,556	6.86%	733	733	733	733
Migami, Inc.       4,286,000       3.77%       2,830       2,830       2,830       -         KT&G Pars (*2)       459,998       99.99%       479       479       479       -         KT&G Rus L.L.C. (*2)       (*6)       99.00%       793       793       793       -         Korea Carbon Finance, Inc.(*2)       100,000       20.00%       500       500       500       -         SJ Biomed Corporation       285,714       16.00%       1,000       1,000       1,000       -         The Korea Economic Daily       287       0.00%       5       5       5       5         Ddrug Co., Ltd. (*5)       -       -       -       -       -       -       4         Husis Co., Ltd. (*3)       700,000       6.90%       210       -       -       -       -         Yungjin Co., Ltd. (*3)       16,760       41.90%       168       -       -       -       -	OCT USA, Inc.	48,780	19.97%	927	927	927	927
KT&G Pars (*2)       459,998       99.99%       479       479       479       -         KT&G Rus L.L.C. (*2)       (*6)       99.00%       793       793       793       -         Korea Carbon Finance, Inc.(*2)       100,000       20.00%       500       500       500       -         SJ Biomed Corporation       285,714       16.00%       1,000       1,000       1,000       -         The Korea Economic Daily       287       0.00%       5       5       5       5         Ddrug Co., Ltd. (*5)       -       -       -       -       -       -       4         Husis Co., Ltd. (*3)       700,000       6.90%       210       -       -       -         Yungjin Co., Ltd. (*3)       16,760       41.90%       168       -       -       -	Dream Hub PFV Co., Ltd.	3,000,000	1.50%	15,000	15,000	15,000	75
KT&G Rus L.L.C. (*2)       (*6)       99.00%       793       793       793       793         Korea Carbon Finance, Inc.(*2)       100,000       20.00%       500       500       500       -         SJ Biomed Corporation       285,714       16.00%       1,000       1,000       1,000       -         The Korea Economic Daily       287       0.00%       5       5       5       5         Ddrug Co., Ltd. (*5)       -       -       -       -       -       -       -       4         Husis Co., Ltd. (*3)       700,000       6.90%       210       -       -       -       -         Yungjin Co., Ltd. (*3)       16,760       41.90%       168       -       -       -       -	Migami, Inc.	4,286,000	3.77%	2,830	2,830	2,830	-
Korea Carbon Finance, Inc.(*2)       100,000       20.00%       500       500       500       -         SJ Biomed Corporation       285,714       16.00%       1,000       1,000       1,000       -         The Korea Economic Daily       287       0.00%       5       5       5       5         Ddrug Co., Ltd. (*5)       -       -       -       -       -       -       4         Husis Co., Ltd. (*3)       700,000       6.90%       210       -       -       -         Yungjin Co., Ltd. (*3)       16,760       41.90%       168       -       -       -	KT&G Pars (*2)	459,998	99.99%	479	479	479	-
SJ Biomed Corporation       285,714       16.00%       1,000       1,000       1,000       -         The Korea Economic Daily       287       0.00%       5       5       5       5         Ddrug Co., Ltd. (*5)       -       -       -       -       -       -       4         Husis Co., Ltd. (*3)       700,000       6.90%       210       -       -       -         Yungjin Co., Ltd. (*3)       16,760       41.90%       168       -       -       -	KT&G Rus L.L.C. (*2)	(*6)	99.00%	793	793	793	-
The Korea Economic Daily     287     0.00%     5     5     5       Ddrug Co., Ltd. (*5)     -     -     -     -     -     4       Husis Co., Ltd. (*3)     700,000     6.90%     210     -     -     -       Yungjin Co., Ltd. (*3)     16,760     41.90%     168     -     -     -	Korea Carbon Finance, Inc.(*2)	100,000	20.00%	500	500	500	-
Ddrug Co., Ltd. (*5)       -       -       -       -       -       4         Husis Co., Ltd. (*3)       700,000       6.90%       210       -       -       -         Yungjin Co., Ltd. (*3)       16,760       41.90%       168       -       -       -	SJ Biomed Corporation	285,714	16.00%	1,000	1,000	1,000	-
Husis Co., Ltd. (*3)       700,000       6.90%       210       -       -       -         Yungjin Co., Ltd. (*3)       16,760       41.90%       168       -       -       -	The Korea Economic Daily	287	0.00%	5	5	5	5
Yungjin Co., Ltd. (*3) 16,760 41.90% 168	Ddrug Co., Ltd. (*5)	-	-	-	-	-	4
<del></del>	Husis Co., Ltd. (*3)	700,000	6.90%	210	-	-	-
Yungjin Health Co., Ltd. (*3) 17,900 29.80% 90	Yungjin Co., Ltd. (*3)	16,760	41.90%	168	-	_	-
	Yungjin Health Co., Ltd. (*3)	17,900	29.80%	90			
<b>34,843 28,085 28,085 34,166</b>				34,843	28,085	28,085	34,166
Total <u>W 277,152 333,203 333,203 252,969</u>	Total		₩	<u>√ 277,152</u>	333,203	333,203	252,969

<sup>(\*1)</sup> As REXAHN Pharmaceuticals, Inc. was listed on American Stock Exchange in the period ended September 30, 2008, REXAHN Pharmaceuticals, Inc. is recorded at the reasonably adjusted value of the market price established in American Stock Exchange. Celltrion, Inc. was listed on Korean Securities Dealers Automated Quotations in the period ended September 30, 2008, Celltrion, Inc. was recorded at fair value.

# Notes to Consolidated Financial Statements

(Unaudited)

September 30, 2008 and 2007

# 8 <u>Available-for-sale Securities, Continued</u>

#### (a) Equity securities (non-current), Continued

- (\*2) Investments in small affiliates are accounted for under the cost method for investments since the effect on their financial statements of applying the equity method is not material.
- (\*3) In the prior period, the Company wrote off its investments in Nexgen Biotechnologies, Inc., Lifenza, Inc., Cosmo Tobacco Co., Ltd., Husis Co., Ltd., Yungjin Co., Ltd. and Yungjin Health Co., Ltd. as their decline in value was judged to be other than temporary. Other than the above securities, non-marketable securities were recorded at cost since fair value is not available or readily determinable.
- (\*4) The liquidation process of KT&G Mongolia LLC was completed in the period ended September 30, 2008, the Company recorded a gain on sale of available-for-sale securities of \( \frac{\text{W}}{80} \) million.
- (\*5) The Company disposed of its investment in Ddrug Co., Ltd. and recognized a loss on sale of available-for-sale securities of W4 million in the period ended September 30, 2008.
- (\*6) Stock certificates are not issued.

# (b) Debt securities

				Book value		
In millions of Won	Interest rate per annum	Acquisition cost	Fair value	September 30, 2008	December 31, 2007	
Current assets: Government and municipal bonds Oscotech, Inc.	2.5 ~ 4.0% ¥ 10.0%	¥ 73 1,000	73 1,000	73 1,000	92	
		1,073	1,073	1,073	92	
Non-current assets: Government and municipal bonds	2.5 %	2,105	2,105	2,105	2,129	
Oscotech, Inc. Litepharmtech, Inc.	8.0%	1,000	1,000	1,000	1,000 1,000	
		3,105	3,105	3,105	4,129	
	¥	<b>V</b> 4,178	4,178	4,178	4,221	

<sup>(\*)</sup> The Company recorded an interest income of W15 million for the period ended September 30, 2008.

## (c) Changes in unrealized gains

(i) Changes in unrealized gains of valuation of available-for-sale securities for the nine-month period ended September 30, 2008 are summarized as follows:

In millions of Won	_	Amount including tax effect	Tax effect	Amount, net of tax effect	
<b>Beginning balance</b> Changes in unrealized gain	₩	2,897 59,912	(797) (16,476)	_/	
Ending balance	₩	62,809	(17,273)	45,536	

# Notes to Consolidated Financial Statements (Unaudited)

September 30, 2008 and 2007

# 8 Available-for-sale Securities, Continued

- (c) Changes in unrealized gains, Continued
  - (ii) Changes in unrealized gains of valuation of available-for-sale securities for the year ended December 31, 2007 are summarized as follows:

In millions of Won	_	Amount including tax effect	Tax effect	Amount, net of tax effect	
<b>Beginning balance</b> Changes in unrealized gain	₩	21,971 (19,074)	(6,042) 5,245	15,929 (13,829)	
Ending balance	₩	2,897	(797)	2,100	

# 9 Equity Method Investment Securities

(a) Investments in companies accounted for using the equity method as of September 30, 2008 were as follows:

In millions of Won, except percentage of ownership

Company	Percentage of ownership	of		Market value or net assets	Balance at September 30, 2008
<b>Unlisted</b> KGC Sales Co., Ltd.	99.99%	₩	1,500	2,828	2,486

Investments in companies accounted for using the equity method as of December 31, 2007 were as follows:

In millions of Won, except percentage of ownership

Company	Percentage of ownership		Cost	Market value or net assets	Balance at December 31, 2007
<b>Unlisted</b> KGC Sales Co., Ltd. KT&G Tutun Mamulleri Sanayi	100.00%	₩	1,500	2,319	2,299
ve Ticaret A.S. (*1)	99.99%	_	33,670	33,670	33,670
		₩	35,170	35,989	35,969

(\*1) The Company used unaudited financial statements of KT&G Tutun Mamulleri Sanayi ve Ticaret A.S. when applying the equity method of accounting. In the subsequent period, the Company adjusted the difference between the unaudited and audited results. Historically, the differences have been immaterial.

# Notes to Consolidated Financial Statements (Unaudited)

September 30, 2008 and 2007

# 9 Equity Method Investment Securities, Continued

(b) Details of eliminated unrealized gains from inter-company transactions for the nine-month period ended September 30, 2008 are summarized as follows:

In millions of Won	2008						
	Beginning <u>balance</u>		Increase	Realized amount	Ending balance		
KGC Sales Co., Ltd.	₩	20	342	(20)	342		

Details of eliminated unrealized gains from inter-company transactions for the year ended December 31, 2007 are summarized as follows:

	2007					
In millions of Won	Beginning balance		Increase	Realized amount	Ending balance	
KGC Sales Co., Ltd.	₩	149	20	(149)	20	

(c) Changes in the opening and closing balances of investments in companies accounted for using the equity method for the nine-month period ended September 30, 2008 were as follows:

In millions of Won except percentage of ownership

	2008							
Company	Percentage of ownership	Balance at January 1, 2008	Net Income	Other Decrease (*)	Balance at September 30, 2008			
KGC Sales Co., Ltd. KT&G Tutun Mamulleri	100.00% <del>W</del>	2,299	187	-	2,486			
Sanayi ve Ticaret A.S.	99.99%	33,670		(33,670)				
	₩	35,969	187	(33,670)	2,486			

<sup>(\*)</sup> Other decrease was due to change of subsidiaries in consolidation.

Changes in the opening and closing balances of investments in companies accounted for using the equity method for the year ended December 31, 2007 were as follows:

2007

In millions of Won except percentage of ownership

			2007		
Company	Percentage of ownership	Balance at January 1, 2007	Net Income	Other Increase (*)	Balance at December 31, 2007
KGC Sales Co., Ltd. KT&G Tutun Mamulleri	100.00% <del>W</del>	1,111	1,188	-	2,299
Sanayi ve Ticaret A.S.	99.99%			33,670	33,670
	₩	1,111	1,188	33,670	35,969

(\*) Other increase was due to reclassification from available-for-sale securities.

# Notes to Consolidated Financial Statements

(Unaudited)

September 30, 2008 and 2007

# 9 Equity Method Investment Securities, Continued

(d) Summarized financial information of equity method investment securities as of and for the ninemonth period ended September 30, 2008 is as follows:

In millions of Won

			Total		
Affiliate	Tota	al assets	liabilities	Sales	Net income
KGC Sales Co., Ltd.	₩	7,844	5,016	11,531	509

Summarized financial information of equity method investment securities as of and for the year ended December 31, 2007 is as follows:

In millions of Won

Affiliate		Total assets	Total liabilities	Sales	Net income
KGC Sales Co., Ltd.	₩	6,739	4,420	18,067	1,059
KT&G Tutun Mamulleri Sanayi ve Ticaret A.S.		37,973	4,303	-	(1,608)

# 10 <u>Transactions and Balances with Related Companies</u>

(a) The Company's subsidiaries as of September 30, 2008 were as follows:

Controlled subsidiary(*)	Ownership(%)		
Cosmo Tabacco Co., Ltd.	40.00%		
Korea Tabacos do Brasil Ltda.	99.90%		
Korea Islet Transplantation Institute, Inc.	48.25%		
KGC Sales Co., Ltd.	100.00%		
Yungjin Distribution Co., Ltd.	41.90%		
KT&G Pars	99.99%		
KT&G Rus L.L.C.	99.00%		

<sup>(\*)</sup> Controlled subsidiaries represent majority-owned entities by either the Company or a controlled subsidiary as well as other entities where the Company or its controlled subsidiary owns more than 30% of total outstanding common stock and is the largest shareholder.

# **Notes to Consolidated Financial Statements**

(Unaudited)

September 30, 2008 and 2007

# 10 Transactions and Balances with Related Companies, Continued

(b) Significant transactions and account balances which occurred in the normal course of business with related companies for the three- and nine-month periods ended September 30, 2008 and 2007 and as of September 30, 2008 and December 31, 2007 are summarized as follows:

# (i) Sales

		200	8	2007		
In millions of Won	_	Three months	Nine months	Three months	Nine months	
KGC Sales Co., Ltd. KT&G Tutun Mamulleri	₩	4,020	9,739	3,537	10,386	
Sanayi ve Ticaret A.S.		-	-	293	372	
KT&G Monglia LLC.		-	-	468	1,148	
KT&G USA, Inc.		-	-	-	1,694	
KT&G Pars	_	269	555			
	₩	4,289	10,294	4,298	13,600	

# (ii) Purchases and other expenses

		200	8	2007		
In millions of Won	_	Three months	Nine months	Three months	Nine months	
Korea Tabacos do Brasil Ltda.	₩_	54	129	58	106	
	₩_	54	129	58	106	

# (iii) Due from affiliates

		September 30, 2008			December 31, 2007			
In millions of Won		Trade accounts receivable	Other	Total	Trade accounts receivable	Other	Total	
KT&G Mongolia LLC KT&G Pars KGC Sales Co., Ltd. KT&G Tutun Mamulleri	₩	586 3,086	- 2,937 -	3,523 3,086	316 - 3,158	238	554 - 3,158	
Sanayi ve Ticaret A.S. Yungjin Health Food Co., Ltd.	•	- 4,310	<u>-</u>	- 4,310	1,127 4,310	- - -	1,127 4,310	
	₩	7,982	2,937	10,919	8,911	238	9,149	

# Notes to Consolidated Financial Statements

(Unaudited)

September 30, 2008 and 2007

# 10 Transactions and Balances with Related Companies, Continued

(c) Due from the stockholders, directors and employees as of September 30, 2008 and December 31, 2007 are summarized as follows:

In millions of Won	Se	eptember 30, 2008	December 31, 2007
Loans for employee housing and tuition	₩	51,791	31,987
Loans to employee stock ownership association		10,340	37,803
Other		49,856	46,004
	₩	111,987	115,794

(d) Details of compensation to top executives for the nine-month period ended September 30, 2008 are summarized as follows:

In millions of Won	Amount		
Short-term payroll Post-retirement payments	<b>₩</b>	8,506 12,039	
	₩	20,545	

# 11 Advance Payments

The Company maintains a contract with the farmers under which they are to grow green ginseng and sell the ginseng to the Company once the product becomes nine years old. As of September 30, 2008 and December 31, 2007, advance payments paid to the farmers in accordance with the contract are as follows:

In millions of Won

Classification	Account		September 30, 2008	December 31, 2007
Two-year old ginseng	Long-term advance payments	₩	47,666	-
Three-year old ginseng	Long-term advance payments		35,236	35,253
Four-year old ginseng Five-year old ginseng	Long-term advance payments Long-term advance payments	_	31,602 26,582	31,749 26,417
			141,086	93,419
Six-year old ginseng	Short-term advance payments	_	37,912	22,870
Total		₩	178,998	116,289

# **Notes to Consolidated Financial Statements**

(Unaudited)

September 30, 2008 and 2007

# 12 Property, Plant and Equipment

Property, plant and equipment at September 30, 2008 and December 31, 2007 are summarized as follows:

In millions of Won		September 30, 2008	December 31, 2007
Property, plant and equipment at cost Accumulated depreciation Accumulated impairment losses	₩	2,609,134 (989,942) (1,554)	2,470,193 (908,684) (2,220)
Property, plant and equipment, net	₩_	1,617,638	1,559,289

(a) Changes in property, plant and equipment for the nine-month period ended September 30, 2008 were as follows:

In millions of Won		January 1, 2008	Change of Subsidiaries	Acquisition	Disposal	Depreciation	Others (*2)	September 30, 2008
Land	₩	431,728	2,526	1,031	(2,365)	-	17,594	450,514
Buildings		523,702	-	7,654	(3,286)	(20,844)	45,743	552,969
Structures		29,228	-	1,132	(146)	(1,986)	3,309	31,537
Machinery and equipment		390,703	-	9,593	(998)	(60,068)	74,960	414,190
Vehicles and other								
transportation equipment		3,354	-	771	(16)	(1,569)	79	2,619
Tools		13,329	-	2,350	(11)	(4,188)	448	11,928
Furniture and fixtures		82,448	106	18,699	(297)	(30,037)	2,969	73,888
Other tangible fixed assets		744	-	-	-	-	-	744
Construction-in-progress(*1)		84,053	25,834	106,639			(137,277)	79,249
	₩	1,559,289	28,466	147,869	(7,119)	(118,692)	7,825	1,617,638

<sup>(\*1)</sup> Construction-in-progress as of September 30, 2008 includes investment on development of new medicines amounting to \(\psi\_25,115\) million.

<sup>(\*2)</sup> Other changes for the nine-month period ended September 30, 2008 include the amount transferred to site for building lotting-out construction as part of inventories amounting to \text{\$\psi}\$3,422 million and the amount transferred from long-term advance payments amounting to \text{\$\psi}\$1,715 million and change in exchange rate amounting to \text{\$\psi}7,501 million.

# **Notes to Consolidated Financial Statements**

(Unaudited)

September 30, 2008 and 2007

# 12 Property, Plant and Equipment, Continued

(b) Changes in property, plant and equipment for the year ended December 31, 2007 were as follows:

In millions of Won	_	January 1, 2007	Change of Subsidiaries/ Merger	Acquisition	Disposal	<b>Depreciation</b>	Other (*2)	December 31, 2007
Land	₩	381,944	-	22,266	(13,592)	-	41,110	431,728
Buildings		499,947	-	7,683	(4,577)	(25,058)	45,707	523,702
Structures		28,557	25	1,822	(296)	(2,454)	1,574	29,228
Machinery and equipment		369,761	-	12,263	(2,554)	(76,365)	87,598	390,703
Vehicles and other								
transportation equipment		5,872	-	763	(225)	(3,131)	75	3,354
Tools		11,523	8	2,940	(28)	(5,163)	4,049	13,329
Furniture and fixtures		79,928	(52)	37,129	(131)	(38,696)	4,270	82,448
Other tangible fixed assets		605	-	139	-	-	-	744
Construction-in-progress(*1)	_	84,607		186,138			(186,692)	84,053
	₩	1,462,744	(19)	271,143	(21,403)	(150,867)	(2,309)	1,559,289

- (\*1) Construction-in-progress as of December 31, 2007 includes investment on development of new medicines amounting to \(\frac{\text{\ti}\text{\texi\text{\text{\text{\text{\text{\text{\text{\texi}\t
- (\*2) Other changes for the year ended December 31, 2007 include losses on impairment of property, plant and equipment amounting to \(\psi\_2,179\) million and the amount transferred to intangible assets.

## 13 Officially Declared Value of Land

The officially declared value of land as of September 30, 2008 and December 31, 2007, as announced by the Minister of Construction and Transportation, were as follows:

		September 30, 2008		September 30, 2008 December 31			31, 2007
In millions of Won	_	Book value	Declared value	Book value	Declared value		
Land Sites for building lotting-out	₩	450,514	1,481,751	431,728	1,373,374		
construction		14,519	50,555	13,204	40,356		

The officially declared value, which is used for government purposes, is not intended to represent fair value.

## 14 <u>Insurance</u>

Buildings, structures, machinery and inventories are insured against fire damage up to \$41,319,251 million as of September 30, 2008 with Dongbu Insurance Co., Ltd. and others. In addition, the Company carries comprehensive automobile insurance, unemployment insurance and workers' accident compensation insurance.

# **Notes to Consolidated Financial Statements**

(Unaudited)

September 30, 2008 and 2007

# 15 Pledged Assets

The following assets were pledged as collateral for the Company's short-term borrowings and long-term borrowings as of September 30, 2008:

In millions of Won

Asset	Lender	Type of borrowings	Borrowing amount	Book value	Collateralized amount
Land, Buildings and Structures	Hana Bank TongYang Investment	Short-term ₩	22,200	31,520	60,050
	Bank Co., Ltd. Woori Investment & Securities	Short-term	3,000		
	Co., Ltd. Hana Bank	Short-term Current portion of	5,000		
		long-term	280		
	Hana Bank	Long-term	2,545		
		₩	33,025	31,520	60,050

# 16 Goodwill

Changes in goodwill for the nine-month period ended September 30, 2008 and the year ended December 31, 2007 were as follows:

In millions of Won	-	2008	2007
Beginning balance	₩	4,007	6,977
Amortization	-	(2,227)	(2,970)
Ending balance	₩_	1,780	4,007

# Notes to Consolidated Financial Statements

(Unaudited)

September 30, 2008 and 2007

# 17 <u>Intangible Assets</u>

Changes in intangible assets for the nine-month period ended September 30, 2008 and the year ended December 31, 2007 were as follows:

In millions of Won		Industrial property rights	2008 Other intangible assets	Total
Net balance at beginning of period	₩	2,224	2,428	4,652
Increases Change of Subsidiaries		259	159 255	159 514
Amortization and impairment Other		(646)	(683) <u>8</u>	(1,329) <u>8</u>
Net balance at end of period	₩	1,837	2,167	4,004
In millions of Won		Industrial property	2007 Other intangible	
		<u>rights</u>	<u>assets</u>	<u>Total</u>
Net balance at beginning of period	₩	3,714	1,557	5,271
Increases Merger Amortization and impairment		425 - (1,915)	1,575 4 (708)	2,000 4 (2,623)
, and deadon and impairment		(1,010)	(, 50)	(2,020)

# 18 Other Non-current Assets

Other non-current assets as of September 30, 2008 and December 31, 2007 are summarized as follows:

In millions of Won	•	otember 0, 2008	December 30, 2007
Long-term financial instruments (note 4)  Long-term trade account receivable, net of allowance for doubtful accounts of \(\psi_7\),657 in 2008 and	₩	8	44
₩7,253 in 2007		109	84
Other investment assets, net of allowance for doubtful accounts of \(\psi_2\),912 in 2008 and 2007 Long-term other receivables, net of allowance for doubtful accounts of \(\psi_10\) in 2008 and 2007		1,787	2,578
		1,017	1,017
	₩	2,921	3,723

# **Notes to Consolidated Financial Statements**

(Unaudited)

September 30, 2008 and 2007

# 19 Other Current Liabilities

Other current liabilities as of September 30, 2008 and December 31, 2007 are summarized as follows:

In millions of Won	September 30, 2008	December 31, 2007
Withholdings	18,937	11,763
Unearned income	164	89
Withholding guarantee deposits received	95	102
Provision for mileage program	6,976	5,108
Derivatives (note 39)	4,246	25
Current portion of long-term borrowings (notes 15 and 21)	280	210
$\forall$	30,698	17,297

# 20 Short-term Borrowings

Short-term borrowings as of September 30, 2008 and December 31, 2007 are summarized as follows:

In millions of Won				Amou	nt
Type of borrowings	Lender	Interest rate per annum	_	September 30, 2008	December 31, 2007
Credit loans	Hana Bank	7.47~7.90%	₩	13,000	13,000
Loans for facilities	Hana Bank	7.64%		8,000	8,000
General Ioan	Hana Bank	6.67%		1,200	1,200
Commercial paper	TongYang Investment				
	Bank Co., Ltd.	7.40%		3,000	-
Commercial paper	SK Securities Co., Ltd.	6.37%		-	5,338
Commercial paper	Woori Investment &				
	Securities Co., Ltd	7.20%		5,000	10,000
Credit Ioans	Korea Exchange Bank	7.88%		5,000	-
Loans for foreign	Standard Chartered	1Y LIBOR			
currency working capital	First Bank Korea Ltd.	+0.80%		-	559
			₩	35,200	38,097

## **Notes to Consolidated Financial Statements**

(Unaudited)

September 30, 2008 and 2007

### 21 <u>Long-term Borrowings</u>

(a) Long-term borrowings as of September 30, 2008 and December 31, 2007 are summarized as follows:

In millions of Won					Amou	int
Type of borrowings	Lender	Maturity date	Interest rate per annum	. =	September 30, 2008	December 31, 2007
Energy Rationalization Fund	Hana Bank					
		2013	4.25%	₩	1,261	1,402
Environmental Management	Hana Bank	March 31,				
Corporation Fund		2017	5.35%	_	1,563	1,541
					2,824	2,943
Less current portion					(280)	(210)
·				-		· · ·
				₩	2,544	2,733

(b) Repayment schedule for the Company's long-term borrowings as of September 30, 2008 is as follows:

In millions of Won

Period ending September 30,	,	mount	
2009	₩	280	
2010		392	
2011		504	
2012		504	
thereafter		1,144	
	₩	2,824	

# KT&G CORPORATION AND SUBSIDIARIES Notes to Consolidated Financial Statements (Unaudited)

September 30, 2008 and 2007

#### 22 Retirement and Severance Benefits

Changes in the retirement and severance benefits for the nine-month period ended September 30, 2008 and the year ended December 31, 2007 are summarized as follows:

In millions of Won	Se	ptember 30, 2008	December 31, 2007	
Estimated retirement and severance benefits at beginning of period	₩	219,494	208,923	
Provision for retirement and severance benefits Reversal of retirement and severance benefits		47,918	40,335 -	
Unearned Stock Compensation		(4,941)	-	
Payments (*)	-	(11,231)	(29,764)	
Estimated retirement and severance				
benefits at end of period		251,240	219,494	
Contribution to the National Pension Fund		(274)	(295)	
Deposit for severance benefits trust		(134,255)	(132,807)	
Net balance at end of period	₩	116,711	86,392	

(\*) Compensations paid with treasury stock amounting to \(\psi\_2,430\) million and \(\psi\_8,247\) million for the nine-month period ended September 30, 2008 and the year ended December 31, 2007 were included.

The Company maintains employees' severance benefit trust arrangements with Samsung Life Insurance Co., Ltd. and others. Under these arrangements, the Company has made a deposit in the aggregate amount equal to 53.4% and 60.5% of the reserve balances of retirement and severance benefits as of September 30, 2008 and December 31, 2007, respectively. This deposit is to be used to make the required payments to the retirees and accounted for as a reduction of the reserve balance.

## Notes to Consolidated Financial Statements

(Unaudited)

September 30, 2008 and 2007

#### 23 Assets and Liabilities Denominated in Foreign Currencies

Details of assets and liabilities denominated in foreign currencies as of September 30, 2008 and December 31, 2007 were as follows:

In millions of Won
In thousands of US dollars, JPY, Euro, GBP Foreign currency and NTD

Won equivalent

		September 30, 2008	December 31, 2007	September 30, 2008	December 31, 2007
Assets:					
Cash and cash equivalents	USD	3,217	9,984 \	<del>V</del> 3,821	9,367
	JPY	6,663	34,467	76	287
	NTD	6,567	1,495	246	43
Trade accounts receivable	USD	229,505	166,988	244,203	156,668
	EUR	1,083	816	1,849	1,127
	JPY	609	250,854	280	2,090
	NTD	2,411	-	90	-
Other receivables Long-term deposits	USD	259	259	307	243
in the Escrow Fund	USD	84,519	71,022	100,384	66,633
		0.47500	0.40.050.1		000 044
Total	USD	317,500	248,253 ₹	•	232,911
	EUR	1,083	816	1,849	1,127
	JPY	7,272	285,321	356	2,377
	NTD	8,978	1,495	336	43
Liabilities:					
Trade accounts payable	USD	3,453	1,351 ₩	<del>V</del> 4,102	1,267
. ,	EUR	3,849	2,535	6,570	3,502
	JPY	23,846	2,613	273	22
Other payables	GBP	225	<u> </u>	481	
Total	USD	3,453	1,351 \	<del>V</del> 4,102	1,267
Total	EUR	3,849	2,535	6,570	3,502
	JPY	23,846	2,613	273	22
	GBP	225	_,515	481	-

#### 24 <u>Commitments and Contingencies</u>

Under the Escrow Statute imposed by those states in the United States of America, where the Company's tobacco products have been sold, the Company is required to make deposits equal to certain percentage of its sales to the Escrow Funds of those state governments. The deposits will be included in the state governments' medical budgets to compensate for any medical costs incurred by those tobacco consumers. Any deposit amounts remaining in the Escrow Funds, unused after 25 years from the dates of the deposits will be refunded to the Company. As of September 30, 2008 and December 31, 2007, the Company made deposits of \text{\text{\$\psi}100,384 million} and \text{\text{\$\psi}66,633 million}, respectively which were recorded long-term deposits in Escrow Funds in the accompanying consolidated balance sheets.

As of September 30, 2008, four tobacco lawsuits claiming damages of \(\frac{\text{W759}}{\text{million}}\) million were filed against the Company and the Korean government. The Company is also involved in 15 other lawsuits and claims for alleged damages. As the ultimate outcome of those lawsuits and claims cannot be reasonably estimated as of September 30, 2008, the amount of liabilities has not been estimated.

## Notes to Consolidated Financial Statements

(Unaudited)

September 30, 2008 and 2007

#### 24 Commitments and Contingencies, Continued

As of September 30, 2008, the Company has provided the National Agricultural Cooperative Federation ("NACF") and other banks, with guarantees in the aggregate amount of \(\psi\)11,993 million for the customers who made a financing agreement with the financial institutions.

As of September 30, 2008, the Company has entered into Letter of Credit agreements with NACF and several financial institutions in the amount of USD 128,500 thousand.

As of September 30, 2008, the Company has an export guaranty insurance coverage of USD 34,900 thousand with the Korea Export Insurance Corporation in connection with its tobacco exports.

As of September 30, 2008, the Company has been provided with a foreign currency payment guarantee for local dealers for the Company's tobacco products in Russia and other countries. The guarantee provided by Korea Exchange Bank and others is for payments of duty and other tax imposed on the dealers covering up to USD 90,000 thousand,

The Company entered into an overdraft agreement with a limit of \W10,000 million with the NACF as of September 30, 2008.

The Company and 28 other companies were provided with payment guarantees of \(\foating{\psi}\)240,000 million by Seoul Guarantee Insurance Co.,Ltd. in relation to Yongsan International Commercial Development Project.

The Company maintains a contract with the farmers who grow nine-year old green ginseng for purchase volume guarantees. As of September 30, 2008, advance payments to the farmers in accordance with the contract amounted to \text{\psi}178,998 million.

Decided upon the board of director meeting on November 3, 2006, the Company determined to dispose the land located in Pyeongtaek-si Gyeonggi-do for the purpose of improving the financial structure and investment in property. The Company entered into a contract to sell the land for \(\psi\_20,000\) million (including removal cost of production equipment of \(\psi\_6,000\) million). The transacting party may terminate the contract if the land is not included in area for development by Pyeongtaek city.

As of September 30, 2008, the Company has entered into note discounting contracts with Hana Bank and others with the aggregate of lines of credit of \text{\psi}19,000 million, and the amount discounted but not due as of September 30, 2008 totaled \text{\psi}6,697 million.

As of September 30, 2008, the Company provided 2 blank notes and 16 notes amounting to \(\frac{\psi}{27,200}\) million notes and 5 blank checks to Woori Investment & Securities Co.,Ltd. and others as collateral for its short-term and long-term borrowings and trade agreements.

#### **Notes to Consolidated Financial Statements**

(Unaudited)

September 30, 2008 and 2007

#### 25 Capital Adjustments

Capital adjustments as of September 30, 2008 and December 31, 2007 are summarized as follows:

In millions of Won	_	September 30, 2008	December 31, 2007
Treasury stock Unearned stock compensation	₩	(311,692) 4,941	(414,947)
		(306,751)	(414,947)

#### 26 Accumulated Other Comprehensive Income

Accumulated other comprehensive income as of September 30, 2008 and December 31, 2007 are summarized as follows:

In millions of Won	_	September 30, 2008	December 31, 2007
Unrealized gain on valuation of available-for-sale securities Unrealized gain on valuation of equity method	₩	45,536	2,100
investment securities  Gain (Loss) on overseas operations translation	_	132 6,876	1,035 (639)
	₩_	52,544	2,496

#### 27 Retained Earnings

Retained earnings as of September 30, 2008 and December 31, 2007 are summarized as follows:

In millions of Won	_	September 30, 2008	December 31, 2007
Legal reserve	₩	602,937	602,937
Reserve for business expansion		698,881	698,881
Reserve for business rationalization		12,851	12,851
Reserve for research and human resource development		30,000	45,000
Reserve for loss on reissuance of treasury stock		26,646	26,646
Other appropriations		420,000	350,000
Unappropriated retained earnings at end of period	_	442,391	398,421
	₩_	2,233,706	2,134,736

#### (a) Legal Reserve

The Korean Commercial Code requires the Company to appropriate as legal reserve an amount equal to at least 10% of cash dividends for each accounting period until the reserve equals 50% of stated capital. The legal reserve may be used to reduce a deficit or it transferred to common stock in connection with a free issue of shares.

### **Notes to Consolidated Financial Statements**

(Unaudited)

September 30, 2008 and 2007

#### 27 Retained Earnings, Continued

#### (b) Reserve for Business Expansion

Reserve for business expansion was a legal reserve under the old Korea Tobacco and Ginseng Corporation Act, which was abrogated on September 1, 1997; consequently, the existing balance has been regarded as a discretionary reserve thereafter.

#### (c) Reserve for Business Rationalization

Under the Special Tax Treatment Control Law, investment tax credit is allowed for certain investments. The Company was required to appropriate from retained earnings the amount of tax benefits obtained and transfer such amount into a reserve for business rationalization.

#### (d) Reserve for Business Rationalization, Continued

Effective December 11, 2002, the Company is no longer required to establish a reserve for business rationalization despite tax benefits received for certain investments and, consequently, the existing balance is now regarded as a voluntary reserve.

#### (e) Other Reserves

Reserves for research and human resource development and loss on reissuance of treasury stock were appropriated in order to utilize certain tax deduction benefits through the early recognition of future expenditures. These reserves are restored to retained earnings in accordance with the relevant tax laws. Such reserves are taken back into taxable income in the period of restoration. Reserves without specific purposes are restored to retained earnings by a resolution at a general meeting of stockholders.

#### 28 Building Lotting-out Construction Contracts

#### (a) Lotting-out contracts of building construction as of September 30, 2008 are summarized as follows:

	Builder	<b>Construction period</b>	<b>Location</b>
Apartment buildings	SK Engineering & Construction		
in Jeonju	Co., Ltd.	2006 ~ 2009	Jeonju
Apartment buildings in Daejeon	Kyeryong Construction Industrial Co., Ltd.	2008 ~ 2009	Daejeon

#### (b) Details of installment sales as of September 30, 2008 are summarized as follows:

				<u>Recognize</u>	<u>d revenue</u>	
In millions of Won		Expected contract amount	Confirmed contract amount	Prior to 2008	Nine-month period ended September 30, 2008	Unrecognized revenue
Apartment buildings in Jeonju Apartment buildings	₩	284,995	80,927	20,275	32,989	231,731
in Daejeon	_	44,047	20,719		4,111	39,936
	₩_	329,042	101,646	20,275	<u>37,100</u>	271,667

## **Notes to Consolidated Financial Statements** (Unaudited)

September 30, 2008 and 2007

#### 28 Building Lotting-out Construction Contracts, Continued

(c) Cost of installment sales of housing units as of September 30, 2008 are summarized as follows:

In millions of Won	_	Prior to 2008	Nine-month period ended September 30, 2008	Aggregate amount
Apartment buildings in Jeonju Apartment buildings in Daejeon	₩_	13,726 -	22,370 2,841	36,096 2,841
	₩_	13,726	25,211	38,937

#### 29 <u>Selling, General and Administrative Expenses</u>

The details of selling, general and administrative expenses for the three- and nine-month periods ended September 30, 2008 and 2007 were as follows:

	2008		2007		
In millions of Won	Three months	Nine months	Three months	Nine months	
Salaries <del>W</del>	60,966	171,787	51,263	157,702	
Provision for severance benefits	12,275	31,585	7,491	19,727	
Welfare	4,326	17,889	6,435	19,841	
Travel	2,048	6,984	2,221	6,252	
Communications	1,235	3,790	1,151	3,525	
Utilities	1,510	4,660	1,494	4,438	
Taxes and dues	10,046	18,509	7,006	15,637	
Supplies	1,719	3,724	632	2,077	
Uniforms	. 80	140	40	. 81	
Rent	3,091	9,052	2,338	6,237	
Depreciation	13,947	42,489	14,119	42,194	
Amortization	1,169	3,539	1,128	3,358	
Repairs and maintenance	2,283	4,814	1,335	3,823	
Vehicles	2,636	7,003	1,983	5,600	
Insurance	336	1,044	267	926	
Commissions	21,804	63,841	20,200	60,731	
Transportation and warehousing	8,939	22,946	7,553	23,160	
Entertainment	208	1,317	402	1,275	
Conferences	1,458	4,157	1,376	4,506	
Advertising	49,468	133,906	43,045	118,458	
Training	2,724	6,493	2,305	7,004	
Prizes and rewards	465	4,660	341	1,410	
Cooperation	137	824	156	543	
Normal research and development	5,122	14,128	5,229	15,496	
Sample	9	21	4	7	
Bad debts	6,875	12,977	-	4,027	
Other	287	1,003	322	1,188	
W	215,163	593,282	179,836	529,223	

#### **Notes to Consolidated Financial Statements**

(Unaudited)

September 30, 2008 and 2007

#### 30 Added Value

The components of manufacturing costs and selling, general and administrative expenses which are necessary in calculating added value for the three- and nine-month periods ended September 30, 2008 and 2007 were as follows:

		2008		2007		
In millions of Won	_	Three months	Nine months	Three months	Nine months	
Wages and salaries	₩	104,085	292,367	89,255	274,464	
Provision for severance benefits		22,085	47,918	12,530	29,017	
Employee welfare		11,460	35,522	10,158	30,565	
Rent		7,274	17,216	4,506	12,426	
Depreciation		39,106	118,692	38,322	111,442	
Taxes and dues		11,529	21,663	8,254	18,449	

#### 31 Employee Welfare and Contributions to Society

For employee welfare, the Company maintains a refectory, infirmary, athletic facilities, scholarship fund, workmen's accident compensation insurance, unemployment insurance and medical insurance. The amounts of welfare spent for the nine-month periods ended September 30, 2008 and 2007 were estimated at \$W\$35,522\$ million and \$W\$30,565\$ million, respectively.

The Company donated  $\mbox{$W$26,468}$  million and  $\mbox{$W$15,523}$  million to KT&G Social Welfare Foundation and others for the nine-month periods ended September 30, 2008 and 2007, respectively.

#### 32 Income Taxes

(a) The Company was subject to income taxes on taxable income at the following normal tax rates:

Taxable income	Tax rate
Up to ₩100 million	14.3%
Over ₩100 million	27.5%

(b) The components of income tax expense for the three- and nine-month periods ended September 30, 2008 and 2007 are summarized as follows:

		2008	3	2007			
In millions of Won	<u>-</u>	Three months	Nine months	Three months	Nine months		
Current income tax expense Deferred income tax expense Income tax expense charged	₩	82,431 29,978	246,878 38,764	119,299 (1,112)	262,294 6,777		
directly to stockholders' equity	-	(16,396)	(18,549)	(37,565)	(40,684)		
Income tax expense	₩	96,013	267,093	80,622	228,387		

## **Notes to Consolidated Financial Statements**

(Unaudited)

September 30, 2008 and 2007

#### 32 Income Taxes, Continued

(c) The income tax expense calculated by applying the statutory tax rates differs from the actual income tax expense for the three- and nine-month periods ended September 30, 2008 and 2007 for the following reasons:

		200	8	2007		
In millions of Won	-	Three months	Nine months	Three months	Nine months	
<b>Tax at the applicable statutory tax rate</b> Adjustments:	₩	100,215	284,084	86,704	235,767	
Non-taxable income		508	(15,906)	(65)	(5,433)	
Non-deductible expense		1,690	4,149	1,034	2,457	
Tax credit		(1,644)	(5,004)	(1,209)	(3,884)	
Changes in valuation allowances for deferred income tax assets (liabilities) arisen from equity in income of affiliates Additional income taxes for prior period		(4,791)	918	(4,718)	610	
(Refund of prior year's income taxes)		_	(1,120)	828	930	
Other	-	35	(28)	(1,952)	(2,060)	
Income tax expense	₩	96,013	267,093	80,622	228,387	

- (d) The effective tax rates, after adjustments for certain differences between amounts reported for financial accounting and income tax purposes, were approximately 29.16% and 30.85% for the nine-month periods ended September 30, 2008 and 2007.
- (e) The Company did not recognize a deferred tax liability in the amount of ₩53,408 million and ₩ 58,200 million arising from the taxable temporary differences associated with affiliates as of September 30, 2008 and December 31, 2007, respectively, since non-taxable dividend income is excluded from equity in income of affiliates in the calculation of deferred tax liabilities. Also the Company did not recognize a deferred tax liability in the amount of ₩6,914 million and ₩3,450 million arising from the taxable temporary differences as of September 30, 2008 and December 31, 2007, respectively.
- (f) The Company did not recognize a deferred tax asset in the amount of \(\pmu30,805\) million and \(\pmu31,749\) million arising from the deductible temporary differences associated with affiliates as of September 30, 2008 and December 31, 2007, respectively, since there is a remote possibility that the Company will dispose of its investments in affiliates in the foreseeable future. In addition, the Company did not recognize a deferred tax asset in the amount of \(\pmu53,632\) million and \(\pmu56,112\) million arising from other deductible temporary differences as of September 30, 2008 and December 31, 2007, respectively.
- (g) Deferred tax assets and liabilities that were directly charged or credited to accumulated other comprehensive income for the nine-month periods ended September 30, 2008 and 2007 were as follows:

In millions of Won

		2008	2007
Gain on reissuance of treasury stock Unrealized gain on valuation of available-for-sale securities Unrealized loss on valuation of equity method investments	₩	1,659 16,476 -	37,728 2,975 (2)
Losses on overseas operations translation		414	(17)
	₩	18,549	40,684

## Notes to Consolidated Financial Statements

(Unaudited)

September 30, 2008 and 2007

#### 32 Income Taxes, Continued

(h) Under SKAS No. 16, Income Taxes, the deferred tax amounts should be presented as a net current asset or liability and a net non-current asset or liability. In addition, the Company is required to disclose aggregate deferred tax assets (liabilities). As of September 30, 2008, details of aggregate deferred tax assets (liabilities) were as follows:

In millions of Won		Temporary differences	Deferred tax assets (liabilities)	
	-	at September 30, 2008	Current	Non-current
Assets:				
Provision for retirement and severance benefits	₩	176,572	-	44,380
Loss on valuation of inventories		12,418	212	-
Depreciation		17,385	-	4,172
Bad debt		40,808	6,168	-
Impairment losses on property, plant and equipment		4,719	-	697
Impairment losses on available-for-sale security		8,089	-	2,097
Impairment losses on intangible assets		2,266	-	451
Accrued expense		23,238	6,390	-
Donation in excess of tax limit	_	42,617	4,500	7,221
	_	328,112	17,270	59,018
Liabilities:				
Deposit for severance benefits trust Reserve for research and		(134,240)	-	(36,169)
human resource development		(29,973)	-	(8,242)
Equity method investment securities		(507,987)	-	(133,010)
Reserve for losses on reissuance of treasury stock		(26,646)	-	(7,328)
Available-for-sale securities		(62,810)	-	(17,273)
Treasury stock		(38,930)	-	(10,706)
Other		(26,885)	(8,438)	948
				C
		(499,359)	8,832	(152,762)
Unused tax losses	-	23,207		
Net differed tax asset(liability)	₩	(476,152)	8,832	(152,762)

## **Notes to Consolidated Financial Statements** (Unaudited)

September 30, 2008 and 2007

#### 33 Earnings Per Share

#### (a) Basic earnings per share

Basic earnings per share for the nine-month periods ended September 30, 2008 and 2007 were computed as follows:

In millions of Won except share information	_	2008	2007
Controlling interest in net income per accompanying consolidated statements of income Weighted-average number of shares outstanding	₩	649,186 130,558,756	526,755 <u>132,594,933</u>
Basic earnings per share in Korean Won	₩	4,972	3,973

Basic earnings per share for the three-month periods ended September 30, 2008 and 2007 were computed as follows:

In millions of Won except share information		2008	2007
Controlling interest in net income per accompanying consolidated statements of income Weighted-average number of shares outstanding	₩	230,613 130,470,228	198,725 <u>132,306,331</u>
Basic earnings per share in Korean Won	₩	1,768	1,502

(b) Potential dilutive securities which are not included in the calculation of diluted earnings per share for the nine-month period ended September 30, 2008 are summarized as follows:

Туре	Par value in Korean Won	Maturity date	Issuable number of shares
Retirement and severance benefits (share-based payment)	₩ 5,000	February 28 , 2009 ~ March 31, 2010	107,663

## **Notes to Consolidated Financial Statements**

(Unaudited)

September 30, 2008 and 2007

#### 34 Share-based Payment

(a) The details of the Company's stock compensation plan as of September 30, 2008 was as follows:

	KT&G	Yungjin Pharm. Ind. Co., Ltd.
Туре	Performance-based severance pay by share grant(*)	Stock option
Grant date	March 1, 2007~ April 1, 2008	March 27, 2001
Number of shares granted	107,663	400,000
Conditions	Service condition: 1~3 periods Non-market performance condition: long-term evaluation results based on quantified and non-quantified indices	Service condition: 3 periods Exercisable period: 2004.3.27 ~ 2009.3.26 Exercise price: \footnote{\psi}3,200

- (\*) Employees who have been with the Company for more than one period are entitled to performance-based severance payment. Eligible employees have the option to choose the Company's shares for their severance pay. The number of shares that may be granted is subject to the level of performance and service period.
- (b) Share-based payment expense for the nine-month period ended September 30, 2008 is summarized as follows:

In millions of Won		Amount
Share-based payment expense (recognized)		
(retirement and severance payment)	₩	10,729
Remaining expense to be recognized in the future years		4,051

#### 35 Comprehensive Income

Comprehensive income for the nine-month periods ended September 30, 2008 and 2007 was as follows:

In millions of Won	-	2008	2007
Net income	₩	649,002	511,945
Change in fair value of available-for-sale securities, net of tax effect of ₩16,476 in 2008 and ₩2,975 in 2007		43,436	7,841
Increase in unrealized gain on valuation of equity method investments, net of tax effect of \(\fomage 0\) in 2008			
and <del>W</del> (2) in 2007		-	(622)
Change in translation adjustments, net of tax effect of \times 414 in 2008 and \times (17) in 2007		7,515	803
Other	-	(903)	
Comprehensive income	₩	699,050	519,967
Controlling company's interest Minority interest	₩	699,234 (184)	534,855 (14,888)

#### **Notes to Consolidated Financial Statements**

(Unaudited)

September 30, 2008 and 2007

#### 36 Segment Information

- (a) The Company has three reportable operating segments manufacturing and selling tobacco (the tobacco segment), manufacturing and selling ginseng products (the ginseng segment), and other operations.
- (b) Information on each operating segment as of and for the nine-month period ended September 30, 2008 was as follows:

In millions of Won	Tobacco	Ginseng	Other operations	Consolidation adjustment	Total
Sales	₩ 1,895,200	482,881	117,105	(42,117)	2,453,069
Operating income	697,897	160,733	1,247	(2,124)	857,752
Total assets	4,322,852	699,373	107,361	(725,237)	4,404,349

(c) Information on each operating segment as of and for the nine-month period ended September 30, 2007 was as follows:

In millions of Won	Tobacco	Ginseng	Other operations	Consolidation adjustment	Total
Sales	₩ 1,796,184	401,668	93,575	(24,047)	2,267,380
Operating income (loss)	629,150	127,659	(5,658)	9,532	760,683
Total assets	4,499,371	623,341	113,137	(563,395)	4,672,454

#### 37 Non-cash Investing and Financing Activities

Significant non-cash investing and financing activities for the nine-month periods ended September 30, 2008 and 2007 are summarized as follows:

In millions of Won		2008	2007
Retirement of treasury stock	₩	209,767	269,410
Compensation by treasury stock		5,982	2,999
Severance pay by treasury stock		2,430	6,336

## KT&G CORPORATION AND SUBSIDIARIES **Notes to Consolidated Financial Statements**

(Unaudited)

September 30, 2008 and 2007

#### 38 Consolidated Net Income and Net Income in Minority Interest

Consolidated net income and net income in minority interest for the nine-month period ended September 30, 2008 was as follows:

In millions of We except percentage of ownership	age	Adjusted net income		Minority interest in net income		Controlling interest in net income		
Company	Non- consoli- dated net income (loss)	Adjust- ments (*)	Adjusted net income (loss)	Equity ownership of minority interest(%)	Net income in minority interest	Net income (loss) before goodwill amortization	Goodwill amorti- zation	Control- ling interest in net income
KT&G	₩ 648,941	(111,249)	537,692	0.00%	-	537,692	(2,227)	535,465
KGC	116,392	(312)	116,080	0.00%	-	116,080	-	116,080
KGHK	528	-	528	0.00%	-	528	-	528
TAI	685	(98)	587	0.00%	-	587	-	587
YJPI	(445)	32	(413)	44.50%	(184)	(229)	-	(229)
KTMST	(3,245)		(3,245)	0.01%		(3,245)		(3,245)
	₩_762,856_	(111,627)	651,229		(184)	651,413	(2,227)	649,186

<sup>(\*)</sup> Adjustments represent reversal of equity income (loss) of subsidiaries and unrealized income from intercompany transactions.

### **Notes to Consolidated Financial Statements**

(Unaudited)

September 30, 2008 and 2007

#### 39 <u>Derivative Instruments</u>

(a) The Company entered into foreign currency forward and foreign currency option contracts to hedge foreign currency risk of accounts receivable. Details of the contracts as of September 30, 2008 were as follows:

In Won and thousands of US dollars

Derivative Instrument	Contractor	Contract position	Exchange rate	Contract date	Expiration date	Contract amount
Currency option	Korea Exchange	Call Option Sell	₩ 988	March 11, 2008	October 29, 2008~	USD 12,000
·	Bank	Put Option Buy			March 27, 2009	USD 6,000
	Citibank,N.A., Seoul	Call Option Sell	₩ 989	March 12, 2008	October 29, 2008~	USD 10,000
		Put Option Buy			February 25, 2009	USD 5,000

(b) Details of gain and loss on valuation of derivative instruments for the nine-month periods ended September 30, 2008 and 2007 are as follows:

In millions of Won	_	2008	2007
Currency forward Currency option	₩ _	- (4,246)	69
	₩_	(4,246)	69